

Spike mutation D614G alters SARS-CoV-2 fitness

Nature

592, 116-121

DOI: [10.1038/s41586-020-2895-3](https://doi.org/10.1038/s41586-020-2895-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. <i>Cell Host and Microbe</i> , 2020, 28, 867-879.e5.	5.1	316
2	Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	203
3	Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses. <i>Microorganisms</i> , 2020, 8, 1840.	1.6	14
4	Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. <i>Viruses</i> , 2020, 12, 1289.	1.5	35
5	Aislamiento y caracterización de una cepa temprana de SARS-CoV-2 durante la epidemia de 2020 en Medellín, Colombia. <i>Biomedica</i> , 2020, 40, 148-158.	0.3	17
6	Antigenic variation of SARS-CoV-2 in response to immune pressure. <i>Molecular Ecology</i> , 2021, 30, 3548-3559.	2.0	27
7	SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. <i>Viruses</i> , 2020, 12, 1465.	1.5	35
8	Genomic Epidemiology of the First Wave of SARS-CoV-2 in Italy. <i>Viruses</i> , 2020, 12, 1438.	1.5	39
9	Emergence of a Highly Fit SARS-CoV-2 Variant. <i>New England Journal of Medicine</i> , 2020, 383, 2684-2686.	13.9	144
10	The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9309.	1.8	27
11	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 192-203.	1.0	165
12	High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa551.	0.4	26
13	One year update on the COVID-19 pandemic: Where are we now?. <i>Acta Tropica</i> , 2021, 214, 105778.	0.9	142
14	A Gapless, Unambiguous RNA Metagenome-Assembled Genome Sequence of a Unique SARS-CoV-2 Variant Encoding Spike S813I and ORF1a A859V Substitutions. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 123-128.	1.0	5
15	The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 104-107.	1.0	85
16	Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 108-115.	1.0	79
17	Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. <i>Cell</i> , 2021, 184, 64-75.e11.	13.5	843
18	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. <i>Journal of Proteome Research</i> , 2021, 20, 139-153.	1.8	14

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 replicates in respiratory ex vivo organ cultures of domestic ruminant species. <i>Veterinary Microbiology</i> , 2021, 252, 108933.	0.8	48
20	The impact of oxidative stress damage induced by the environmental stressors on COVID-19. <i>Life Sciences</i> , 2021, 264, 118653.	2.0	41
21	Functional and druggability analysis of the SARS-CoV-2 proteome. <i>European Journal of Pharmacology</i> , 2021, 890, 173705.	1.7	34
22	Chemical design principles of next-generation antiviral surface coatings. <i>Chemical Society Reviews</i> , 2021, 50, 9741-9765.	18.7	31
23	One Year in: Lessons from China's Fight Against COVID-19. <i>China CDC Weekly</i> , 2021, 3, 128-129.	1.0	1
24	The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. <i>International Journal of Biological Sciences</i> , 2021, 17, 1476-1485.	2.6	23
26	Population Dynamics and Structural Effects at Short and Long Range Support the Hypothesis of the Selective Advantage of the G614 SARS-CoV-2 Spike Variant. <i>Molecular Biology and Evolution</i> , 2021, 38, 1966-1979.	3.5	23
28	Engineering SARS-CoV-2 using a reverse genetic system. <i>Nature Protocols</i> , 2021, 16, 1761-1784.	5.5	137
29	COVID-19-neutralizing antibodies predict disease severity and survival. <i>Cell</i> , 2021, 184, 476-488.e11.	13.5	586
31	SARS-CoV-2 Variants of Concern Have Acquired Mutations Associated With an Increased Spike Cleavage. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
33	The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. <i>Journal of Biological Chemistry</i> , 2021, 296, 100536.	1.6	91
34	Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. <i>Nature</i> , 2021, 591, 293-299.	13.7	579
35	SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. <i>Journal of Basic Microbiology</i> , 2021, 61, 180-202.	1.8	119
36	Impact of New Variants on SARS-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
37	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. <i>MAbs</i> , 2021, 13, 1930636.	2.6	13
38	Cross-Species Tropism and Antigenic Landscapes of Circulating SARS-CoV-2 Variants. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
42	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3799-3809.	1.9	24
45	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167

#	ARTICLE	IF	CITATIONS
48	Role of mutational reversions and fitness restoration in Zika virus spread to the Americas. <i>Nature Communications</i> , 2021, 12, 595.	5.8	29
49	Developing effective siRNAs to reduce the expression of key viral genes of COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1521-1529.	2.6	17
54	Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant. <i>Clinical and Translational Immunology</i> , 2021, 10, e1241.	1.7	18
55	The evolutionary dynamics of endemic human coronaviruses. <i>Virus Evolution</i> , 2021, 7, veab020.	2.2	40
56	SARS-CoV-2 Mutations: An Insight. , 2021, , 551-563.		0
57	A Trans-Complementation System for SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
58	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. <i>Emerging Microbes and Infections</i> , 2021, 10, 1227-1240.	3.0	17
60	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. <i>Emerging Microbes and Infections</i> , 2021, 10, 1881-1889.	3.0	10
61	Educating ethically during COVID-19. <i>International Journal of Ethics Education</i> , 2021, 6, 177-193.	0.6	3
62	Comments on "Development of a PCR-RFLP method for detection of D614G mutation in SARS-CoV-2". <i>Infection, Genetics and Evolution</i> , 2021, 87, 104661.	1.0	5
63	Could new COVID variants undermine vaccines? Labs scramble to find out. <i>Nature</i> , 2021, 589, 177-178.	13.7	81
64	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
68	Making sense of spike D614G in SARS-CoV-2 transmission. <i>Science China Life Sciences</i> , 2021, 64, 1062-1067.	2.3	8
71	Are the emerging SARS-COV-2 mutations friend or foe?. <i>Immunology Letters</i> , 2021, 230, 63-64.	1.1	13
72	A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL ^{pro} Inhibitor PF-00835231 as a Potential New Treatment for COVID-19. <i>Journal of Virology</i> , 2021, 95, .	1.5	94
76	Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1058-1060.	4.8	23
79	Molecular Epidemiology Surveillance of SARS-CoV-2: Mutations and Genetic Diversity One Year after Emerging. <i>Pathogens</i> , 2021, 10, 184.	1.2	29
82	COVID-19 outbreak in Malaysia: Decoding D614G mutation of SARS-CoV-2 virus isolated from an asymptomatic case in Pahang. <i>Materials Today: Proceedings</i> , 2022, 48, 828-836.	0.9	11

#	ARTICLE	IF	CITATIONS
87	The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. <i>ELife</i> , 2021, 10, .	2.8	173
92	A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. <i>Protein Journal</i> , 2021, 40, 260-295.	0.7	24
93	SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2356.	1.8	13
94	Interactive SARS-CoV-2 mutation timemaps. <i>F1000Research</i> , 2021, 10, 68.	0.8	0
95	CRISPR/Cas9-Based Lateral Flow and Fluorescence Diagnostics. <i>Bioengineering</i> , 2021, 8, 23.	1.6	24
97	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1737.	1.8	15
98	Early Diffusion of SARS-CoV-2 Infection in the Inner Area of the Italian Sardinia Island. <i>Frontiers in Microbiology</i> , 2020, 11, 628194.	1.5	2
101	Could mutations of SARS-CoV-2 suppress diagnostic detection?. <i>Nature Biotechnology</i> , 2021, 39, 274-275.	9.4	63
103	SARS-CoV-2 spike D614G change enhances replication and transmission. <i>Nature</i> , 2021, 592, 122-127.	13.7	440
105	The COVID-19 epidemic in Madagascar: clinical description and laboratory results of the first wave, march-september 2020. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 457-468.	1.5	22
109	Functional alterations caused by mutations reflect evolutionary trends of SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2021, 22, 1442-1450.	3.2	32
110	Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity. <i>IScience</i> , 2021, 24, 102116.	1.9	64
111	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. <i>Nature Medicine</i> , 2021, 27, 620-621.	15.2	562
114	D614G and SARS-CoV-2 replication fitness. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 99.	7.1	1
116	Genome Sequences of Three SARS-CoV-2 P.1 Strains Identified from Patients Returning from Brazil to Italy. <i>Microbiology Resource Announcements</i> , 2021, 10, .	0.3	5
117	COVID-19: emergence and mutational diversification of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2021, 14, 756-768.	2.0	17
120	Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 257-264.	2.4	19
124	SARS-CoV-2 variants reveal features critical for replication in primary human cells. <i>PLoS Biology</i> , 2021, 19, e3001006.	2.6	46

#	ARTICLE	IF	CITATIONS
126	SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome. <i>Molecules</i> , 2021, 26, 1409.	1.7	22
127	Stability of SARS-CoV-2 Spike G614 Variant Surpasses That of the D614 Variant after Cold Storage. <i>MSphere</i> , 2021, 6, .	1.3	21
128	Whole genome analysis of more than 10 000 SARS-CoV-2 virus unveils global genetic diversity and target region of NSP6. <i>Briefings in Bioinformatics</i> , 2021, 22, 1106-1121.	3.2	13
131	Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. <i>Viruses</i> , 2021, 13, 439.	1.5	107
132	Animal Hosts and Experimental Models of SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 1-9.	0.8	13
133	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
134	Detection of a SARS-CoV-2 variant of concern in South Africa. <i>Nature</i> , 2021, 592, 438-443.	13.7	1,381
135	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. <i>Npj Vaccines</i> , 2021, 6, 44.	2.9	36
139	Diverse SARS-CoV-2 variants preceded the initial COVID-19 outbreak in Croatia. <i>Archives of Virology</i> , 2021, 166, 1735-1739.	0.9	0
140	Protein N-myristoylation: functions and mechanisms in control of innate immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 878-888.	4.8	53
142	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. <i>PLoS ONE</i> , 2021, 16, e0248348.	1.1	102
143	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
144	Identifying Primate ACE2 Variants That Confer Resistance to SARS-CoV-2. <i>Molecular Biology and Evolution</i> , 2021, 38, 2715-2731.	3.5	22
146	Monitoring of SARS-CoV-2 infection in mustelids. <i>EFSA Journal</i> , 2021, 19, e06459.	0.9	60
148	Benchmarking SARS CoV-2 Infection in the Workplace to Support Continuity of Operations. <i>Journal of Occupational and Environmental Medicine</i> , 2021, 63, 548-556.	0.9	5
149	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. <i>Reviews in Medical Virology</i> , 2021, 31, e2231.	3.9	128
150	Wuhan to World: The COVID-19 Pandemic. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 596201.	1.8	115
151	Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach. <i>Mathematical and Computational Applications</i> , 2021, 26, 25.	0.7	23

#	ARTICLE	IF	CITATIONS
153	The Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense. <i>Viruses</i> , 2021, 13, 394.	1.5	30
154	Δ;Δ²Δ³⁄₄Δ±Δ³⁄₄ΔΔ¹⁄₂Ñ<Δμ S1-ÑÑfΔ±ÑŠΔμΔΔ,Δ¹⁄₂Δ,Ñ†Ñ< Δ±ΔμΔ»Δ°Δ° Ñ<Δ;Δ³⁄₄Δ² Δ²Δ,Ñ€ÑfÑĐ° SARS-CoV-2 Δ¹⁄₄Δ³⁄₄ΔÑfÑ, Δ³		
155	Mutation D614G increases SARS-CoV-2 transmission. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 101.	7.1	22
156	Natural selection in the evolution of SARS-CoV-2 in bats created a generalist virus and highly capable human pathogen. <i>PLoS Biology</i> , 2021, 19, e3001115.	2.6	172
158	Initial Insights Into the Genetic Epidemiology of SARS-CoV-2 Isolates From Kerala Suggest Local Spread From Limited Introductions. <i>Frontiers in Genetics</i> , 2021, 12, 630542.	1.1	11
160	Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. <i>Npj Vaccines</i> , 2021, 6, 39.	2.9	38
162	Analysis of Three Mutations in Italian Strains of SARS-CoV-2: Implications for Pathogenesis. <i>Chemotherapy</i> , 2021, 66, 33-37.	0.8	4
163	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. <i>Nature Medicine</i> , 2021, 27, 917-924.	15.2	617
164	Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level. <i>Pathogens</i> , 2021, 10, 302.	1.2	15
166	Whole-genome sequencing of SARS-CoV-2 reveals the detection of G614 variant in Pakistan. <i>PLoS ONE</i> , 2021, 16, e0248371.	1.1	34
167	Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 620990.	1.2	26
168	Emergence of SARS-CoV-2 Variant: A wake-up call for Pakistan's overburdened healthcare system. <i>Journal of Medical Virology</i> , 2021, 93, 2595-2598.	2.5	2
170	SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3060.	1.8	32
171	COVID-19 Pandemic: What about the Safety of Anti-Coronavirus Nanoparticles?. <i>Nanomaterials</i> , 2021, 11, 796.	1.9	16
174	Nanobody cocktails potentially neutralize SARS-CoV-2 D614G N501Y variant and protect mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	109
175	The 442th amino acid residue of the spike protein is critical for the adaptation to bat hosts for SARS-related coronaviruses. <i>Virus Research</i> , 2021, 295, 198307.	1.1	5
177	Prevalence of COVID-19 and Possible Antigenic Drifts in SARS-CoV-2 Spike Protein in Kurdistan Region-Iraq. <i>Passer Journal</i> , 2021, 3, 0-0.	0.1	0
180	How SARS-CoV-2 first adapted in humans. <i>Science</i> , 2021, 372, 466-467.	6.0	21

#	ARTICLE	IF	CITATIONS
181	The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. <i>PLoS Pathogens</i> , 2021, 17, e1009500.	2.1	91
182	Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2021, 16, e0250780.	1.1	66
183	Vaccine development for emerging infectious diseases. <i>Nature Medicine</i> , 2021, 27, 591-600.	15.2	213
184	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. <i>Cell</i> , 2021, 184, 2362-2371.e9.	13.5	332
185	In Silico Study of Mutational Stability of SARS-CoV-2 Proteins. <i>Protein Journal</i> , 2021, 40, 328-340.	0.7	6
186	In silico characterization of mutations circulating in SARS-CoV-2 structural proteins. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8216-8231.	2.0	11
187	Introduction, Transmission Dynamics, and Fate of Early Severe Acute Respiratory Syndrome Coronavirus 2 Lineages in Santa Clara County, California. <i>Journal of Infectious Diseases</i> , 2021, 224, 207-217.	1.9	2
188	The variant gambit: COVID-19's next move. <i>Cell Host and Microbe</i> , 2021, 29, 508-515.	5.1	305
190	Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score. <i>MSphere</i> , 2021, 6, .	1.3	23
192	Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V. <i>Protein Science</i> , 2021, 30, 1131-1143.	3.1	47
193	On the origin and evolution of SARS-CoV-2. <i>Experimental and Molecular Medicine</i> , 2021, 53, 537-547.	3.2	177
195	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. <i>Biomedicines</i> , 2021, 9, 412.	1.4	22
196	Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern. <i>Microorganisms</i> , 2021, 9, 926.	1.6	48
197	Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain. <i>Scientific Reports</i> , 2021, 11, 9166.	1.6	13
198	Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations. <i>FEBS Letters</i> , 2021, 595, 1454-1461.	1.3	165
199	Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. <i>ACS Central Science</i> , 2021, 7, 792-802.	5.3	59
201	Neurotropic Viruses, Astrocytes, and COVID-19. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 662578.	1.8	40
202	Genomic and epidemiological characteristics of SARS-CoV-2 in Africa. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009335.	1.3	17

#	ARTICLE	IF	CITATIONS
204	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
205	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. <i>Cell</i> , 2021, 184, 2316-2331.e15.	13.5	321
207	Circular intensity differential scattering of light to characterize the coronavirus particles. <i>Journal of the Optical Society of America B: Optical Physics</i> , 2021, 38, 1702.	0.9	9
211	Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2. <i>Viruses</i> , 2021, 13, 638.	1.5	21
212	Immunogenicity and efficacy of one and two doses of Ad26.COVS COVID vaccine in adult and aged NHP. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	55
213	Dissemination and evolution of SARS-CoV-2 in the early pandemic phase in South America. <i>Journal of Medical Virology</i> , 2021, 93, 4496-4507.	2.5	5
214	Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach. <i>Epidemiologia</i> , 2021, 2, 140-161.	1.1	22
215	Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 365-373.	2.0	139
216	Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. <i>Cell</i> , 2021, 184, 2372-2383.e9.	13.5	1,166
217	Structural impact on SARS-CoV-2 spike protein by D614G substitution. <i>Science</i> , 2021, 372, 525-530.	6.0	344
218	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021, 184, 2384-2393.e12.	13.5	848
223	A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. <i>Cell</i> , 2021, 184, 2229-2238.e13.	13.5	51
224	One year of SARS-CoV-2 evolution. <i>Cell Host and Microbe</i> , 2021, 29, 503-507.	5.1	60
225	SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. <i>Cell Host and Microbe</i> , 2021, 29, 522-528.e2.	5.1	173
226	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. <i>Journal of General Virology</i> , 2021, 102, .	1.3	137
227	The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters. <i>Virology</i> , 2021, 556, 96-100.	1.1	17
228	SARS-CoV-2 shifting transmission dynamics and hidden reservoirs potentially limit efficacy of public health interventions in Italy. <i>Communications Biology</i> , 2021, 4, 489.	2.0	23
229	SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. <i>Cell Reports</i> , 2021, 35, 109017.	2.9	77

#	ARTICLE	IF	CITATIONS
230	Fundamental evolution of all <i>Orthocoronavirinae</i> including three deadly lineages descendent from Chiroptera-hosted coronaviruses: SARS-CoV, MERS-CoV and SARS-CoV-2. <i>Cladistics</i> , 2021, 37, 461-488.	1.5	16
231	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021, 29, 516-521.e3.	5.1	199
232	Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671923.	1.6	0
236	SARS-CoV-2 outbreak in Iran: The dynamics of the epidemic and evidence on two independent introductions. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 1375-1386.	1.3	19
237	SARS-CoV-2 variants: A double-edged sword?. <i>Experimental Biology and Medicine</i> , 2021, 246, 1721-1726.	1.1	19
238	Implications of the Novel Mutations in the SARS-CoV-2 Genome for Transmission, Disease Severity, and the Vaccine Development. <i>Frontiers in Medicine</i> , 2021, 8, 636532.	1.2	56
239	Clinical Characteristics and Transmission of COVID-19 in Children and Youths During 3 Waves of Outbreaks in Hong Kong. <i>JAMA Network Open</i> , 2021, 4, e218824.	2.8	48
240	Current and prospective computational approaches and challenges for developing COVID-19 vaccines. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 249-274.	6.6	30
241	Limited cross-species transmission and absence of mutations associated with SARS-CoV-2 adaptation in cats: A case study of infection in a small household setting. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 1606-1616.	1.3	19
242	Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 416-426.	2.9	20
243	Respiratory Co-Infections: Modulators of SARS-CoV-2 Patients' Clinical Sub-Phenotype. <i>Frontiers in Microbiology</i> , 2021, 12, 653399.	1.5	22
244	Coronavirus-2019: Origin and evolution. , 0, 1, 1-6.		0
245	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	1.9	20
246	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. <i>Npj Vaccines</i> , 2021, 6, 67.	2.9	47
247	Mutation in a SARS-CoV-2 Haplotype from Sub-Antarctic Chile Reveals New Insights into the Spike's Dynamics. <i>Viruses</i> , 2021, 13, 883.	1.5	8
248	SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. <i>Nature Communications</i> , 2021, 12, 2642.	5.8	136
249	Testing at scale during the COVID-19 pandemic. <i>Nature Reviews Genetics</i> , 2021, 22, 415-426.	7.7	261
251	Guidelines for Reopening a Nation in a SARS-CoV-2 Pandemic: A Path Forward. <i>Medicina (Lithuania)</i> , 2021, 57, 496.	0.8	4

#	ARTICLE	IF	CITATIONS
254	Minipool testing for SARS-CoV-2 RNA in United States blood donors. <i>Transfusion</i> , 2021, 61, 2384-2391.	0.8	20
255	Phylogenomic analysis of COVID-19 summer and winter outbreaks in Hong Kong: An observational study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100130.	1.3	26
256	The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play. <i>International Journal of Biological Macromolecules</i> , 2021, 179, 1-19.	3.6	17
257	Mutations in the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a Flexible Link to the Fusion Peptide. <i>Biomedicines</i> , 2021, 9, 525.	1.4	28
258	Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants spike protein: an in silico analysis. <i>PLoS ONE</i> , 2021, 16, e0251426.	1.1	10
262	Genomic epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil. <i>BMC Genomics</i> , 2021, 22, 371.	1.2	22
263	The Spike of Concern: The Novel Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1002.	1.5	92
264	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 601-621.	1.3	144
267	Asymptomatic COVID-19: disease tolerance with efficient antiviral immunity against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2021, 13, e14045.	3.3	36
268	SARS-CoV-2 Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1962.	1.0	10
269	Possible effects of air temperature on COVID-19 disease severity and transmission rates. <i>Journal of Medical Virology</i> , 2021, 93, 5358-5366.	2.5	16
270	Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform. <i>Cell Reports Medicine</i> , 2021, 2, 100312.	3.3	44
271	Evolution, Ecology, and Zoonotic Transmission of Betacoronaviruses: A Review. <i>Frontiers in Veterinary Science</i> , 2021, 8, 644414.	0.9	10
272	Inhibition mechanism of SARS-CoV-2 main protease by ebsele and its derivatives. <i>Nature Communications</i> , 2021, 12, 3061.	5.8	149
273	Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. <i>BMJ</i> , The, 2021, 373, n1087.	3.0	59
275	The Longest Infectious Virus Shedding in a Child Infected With the G614 Strain of SARS-CoV-2. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e263-e265.	1.1	6
278	Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5464.	1.8	9
281	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. <i>Wellcome Open Research</i> , 2021, 6, 110.	0.9	14

#	ARTICLE	IF	CITATIONS
282	Cov-MS: A Community-Based Template Assay for Mass-Spectrometry-Based Protein Detection in SARS-CoV-2 Patients. <i>Jacs Au</i> , 2021, 1, 750-765.	3.6	29
283	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. <i>Human Genomics</i> , 2021, 15, 27.	1.4	39
287	Relevant SARS-CoV-2 Genome Variation through Six Months of Worldwide Monitoring. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	6
288	Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. <i>Reviews in Medical Virology</i> , 2022, 32, e2270.	3.9	71
289	Recombinant SARS-CoV-2 genomes circulated at low levels over the first year of the pandemic. <i>Virus Evolution</i> , 2021, 7, .	2.2	38
290	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. <i>Human Gene Therapy</i> , 2021, 32, 541-562.	1.4	9
291	Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil. <i>Viruses</i> , 2021, 13, 1237.	1.5	23
294	Severe Acute Respiratory Syndrome Coronavirus 2: The Emergence of Important Genetic Variants and Testing Options for Clinical Laboratories. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 89-96.	0.4	5
295	Integrated docking and enhanced sampling-based selection of repurposing drugs for SARS-CoV-2 by targeting host dependent factors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9897-9908.	2.0	7
296	SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence. <i>Journal of Clinical Medicine</i> , 2021, 10, 2635.	1.0	36
297	Predicting the development trend of the second wave of COVID-19 in five European countries. <i>Journal of Medical Virology</i> , 2021, 93, 5896-5907.	2.5	2
298	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
299	Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 648005.	1.2	25
300	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. <i>Scientific Reports</i> , 2021, 11, 12740.	1.6	54
302	Landscape-Based Mutational Sensitivity Cartography and Network Community Analysis of the SARS-CoV-2 Spike Protein Structures: Quantifying Functional Effects of the Circulating D614G Variant. <i>ACS Omega</i> , 2021, 6, 16216-16233.	1.6	10
303	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. <i>Viruses</i> , 2021, 13, 1192.	1.5	150
304	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
306	Characterization of SARS-CoV-2 East Java Isolate, Indonesia. <i>F1000Research</i> , 2021, 10, 480.	0.8	5

#	ARTICLE	IF	CITATIONS
307	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. <i>Nature</i> , 2021, 596, 109-113.	13.7	586
309	Middle East respiratory syndrome coronavirus Spike protein variants exhibit geographic differences in virulence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	7
310	Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. <i>PLoS Pathogens</i> , 2021, 17, e1009619.	2.1	40
311	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
313	A Novel SARS-CoV-2 Viral Sequence Bioinformatic Pipeline Has Found Genetic Evidence That the Viral 3' UTR Is Evolving and Generating Increased Viral Diversity. <i>Frontiers in Microbiology</i> , 2021, 12, 665041.	1.5	20
315	A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses. <i>Nature Communications</i> , 2021, 12, 3431.	5.8	89
317	What gastroenterologists should know about SARS-CoV-2 vaccine: World Endoscopy Organization perspective. <i>United European Gastroenterology Journal</i> , 2021, 9, 787-796.	1.6	4
318	SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 676451.	1.8	21
319	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.	13.7	318
320	A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2'-O methylation of its first nucleotide. <i>Nature Communications</i> , 2021, 12, 3287.	5.8	23
323	Replication Kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 Variants of Concern Including Assessment of a B.1.1.7 Mutant Carrying a Defective ORF7a Gene. <i>Viruses</i> , 2021, 13, 1087.	1.5	34
324	SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system. <i>Journal of Translational Medicine</i> , 2021, 19, 246.	1.8	14
327	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. <i>Comptes Rendus - Biologies</i> , 2021, 344, 77-110.	0.1	4
328	SARS-CoV-2 Infects Hamster Testes. <i>Microorganisms</i> , 2021, 9, 1318.	1.6	19
329	Genome-wide analysis of SARS-CoV-2 strains circulating in Vietnam: Understanding the nature of the epidemic and role of the D614G mutation. <i>Journal of Medical Virology</i> , 2021, 93, 5660-5665.	2.5	3
330	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869.	2.2	23
331	A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic. <i>Viruses</i> , 2021, 13, 1098.	1.5	11
332	Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2. <i>Cell Discovery</i> , 2021, 7, 44.	3.1	16

#	ARTICLE	IF	CITATIONS
334	The architecture of the SARS-CoV-2 RNA genome inside virion. <i>Nature Communications</i> , 2021, 12, 3917.	5.8	122
335	An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. <i>Cell</i> , 2021, 184, 3452-3466.e18.	13.5	205
336	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. <i>Journal of Virology</i> , 2021, 95, e0040421.	1.5	34
337	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021, 595, 707-712.	13.7	363
338	Interactive SARS-CoV-2 mutation timemaps. <i>F1000Research</i> , 2021, 10, 68.	0.8	0
339	Computational analysis of protein stability and allosteric interaction networks in distinct conformational forms of the SARS-CoV-2 spike D614G mutant: reconciling functional mechanisms through allosteric model of spike regulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9724-9741.	2.0	11
341	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8
342	Accelerating SARS-CoV-2 low frequency variant calling on ultra deep sequencing datasets. , 2021, , .		5
346	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
347	COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. <i>Frontiers in Genetics</i> , 2021, 12, 693916.	1.1	55
348	The total number and mass of SARS-CoV-2 virions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	187
349	Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8.	13.5	424
351	Mathematical modelling of the second wave of COVID-19 infections using deterministic and stochastic SIRD models. <i>Nonlinear Dynamics</i> , 2021, 106, 1359-1373.	2.7	8
352	COVID-19: 1/4D, N, N, D, NEDμD°D»NCE1/2D3/4NÑ,ÑCE. <i>Biochemistry</i> , 2021, 86, 964-984.	0.0	0
354	Molecular Diagnosis of SARS-CoV-2: Assessing and Interpreting Nucleic Acid and Antigen Tests. <i>Pathogens and Immunity</i> , 2021, 6, 135-156.	1.4	10
355	ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections. <i>Genomics</i> , 2021, 113, 1628-1638.	1.3	8
356	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7425.	1.8	69
357	SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. <i>Journal of Medical Virology</i> , 2021, 93, 6551-6556.	2.5	79

#	ARTICLE	IF	CITATIONS
358	SARS-CoV-2 receptor-binding mutations and antibody contact sites. <i>Antibody Therapeutics</i> , 2021, 4, 149-158.	1.2	12
359	The virological impacts of SARS-CoV-2 D614G mutation. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 712-720.	1.5	21
360	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
362	SARS-CoV-2 serology testing: Progress and challenges. <i>Journal of Immunological Methods</i> , 2021, 494, 113060.	0.6	21
363	Nonlinear Dynamics of the Introduction of a New SARS-CoV-2 Variant with Different Infectiousness. <i>Mathematics</i> , 2021, 9, 1564.	1.1	5
366	SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts. <i>PLoS ONE</i> , 2021, 16, e0255169.	1.1	28
367	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. <i>Current Medical Science</i> , 2021, 41, 1037-1051.	0.7	136
368	V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. <i>Journal of Virology</i> , 2021, 95, e0061721.	1.5	90
369	Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. <i>Phytomedicine</i> , 2021, 87, 153591.	2.3	41
370	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	5.1	421
372	Genetic emergence of B.1.617.2 in COVID-19. <i>New Microbes and New Infections</i> , 2021, 43, 100929.	0.8	45
373	Carbon Nanotube Mask Filters and Their Hydrophobic Barrier and Hyperthermic Antiviral Effects on SARS-CoV-2. <i>ACS Applied Nano Materials</i> , 2021, 4, 8135-8144.	2.4	25
375	Genome-Wide Variation in Betacoronaviruses. <i>Journal of Virology</i> , 2021, 95, e0049621.	1.5	4
376	The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN- β production in vitro. <i>International Immunopharmacology</i> , 2021, 96, 107797.	1.7	13
377	Evolutionary insights into the furin cleavage sites of SARS-CoV-2 variants from humans and animals. <i>Archives of Virology</i> , 2021, 166, 2541-2549.	0.9	13
378	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	5.1	73
381	COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. <i>PLoS Pathogens</i> , 2021, 17, e1009753.	2.1	61
383	The molecular basis for SARS-CoV-2 binding to dog ACE2. <i>Nature Communications</i> , 2021, 12, 4195.	5.8	43

#	ARTICLE	IF	CITATIONS
384	COVID-19: Myths and Reality. <i>Biochemistry (Moscow)</i> , 2021, 86, 800-817.	0.7	10
386	SARS-CoV-2: is there neuroinvasion?. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 32.	2.4	43
388	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
390	Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model. <i>Marine Drugs</i> , 2021, 19, 418.	2.2	29
391	Emerging SARS-CoV-2 variants of concern and potential intervention approaches. <i>Critical Care</i> , 2021, 25, 244.	2.5	186
392	Recent Advances in Two-Dimensional Transition Metal Dichalcogenide Nanocomposites Biosensors for Virus Detection before and during COVID-19 Outbreak. <i>Journal of Composites Science</i> , 2021, 5, 190.	1.4	22
394	CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro. <i>Frontiers in Immunology</i> , 2021, 12, 652223.	2.2	27
395	SARS-CoV-2: Cross-scale Insights from Ecology and Evolution. <i>Trends in Microbiology</i> , 2021, 29, 593-605.	3.5	12
397	Phylogenomics reveals multiple introductions and early spread of SARS-CoV-2 into Peru. <i>Journal of Medical Virology</i> , 2021, 93, 5961-5968.	2.5	15
399	Is increased mortality by multiple exposures to COVID-19 an overseen factor when aiming for herd immunity?. <i>PLoS ONE</i> , 2021, 16, e0253758.	1.1	8
401	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	6.6	190
404	Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 715464.	2.2	11
405	Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains. <i>MBio</i> , 2021, 12, e0159021.	1.8	49
406	A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation. <i>Cell</i> , 2021, 184, 4392-4400.e4.	13.5	69
407	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	2.9	67
409	SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1070.	4.6	188
411	An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. <i>Cell and Bioscience</i> , 2021, 11, 164.	2.1	10
412	SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. <i>MBio</i> , 2021, 12, e0141521.	1.8	33

#	ARTICLE	IF	CITATIONS
413	SARS-CoV-2 genomic surveillance in Costa Rica: Evidence of a divergent population and an increased detection of a spike T1117I mutation. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104872.	1.0	25
416	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. <i>Vaccine: X</i> , 2021, 8, 100098.	0.9	9
417	Liquidâ€“liquid phase separation in human health and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 290.	7.1	231
420	Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 163, 171-186.	1.4	39
422	Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 589-600.	0.5	5
423	A model of the innate immune response to SARS-CoV-2 in the alveolar epithelium. <i>Royal Society Open Science</i> , 2021, 8, 210090.	1.1	4
425	ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 315.	7.1	53
426	Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico. <i>Archives of Virology</i> , 2021, 166, 3173-3177.	0.9	31
427	Monitoring Natural SARS-CoV-2 Infection in Lions (<i>Panthera leo</i>) at the Barcelona Zoo: Viral Dynamics and Host Responses. <i>Viruses</i> , 2021, 13, 1683.	1.5	51
428	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
429	Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. <i>Journal of Virology</i> , 2021, 95, e0097521.	1.5	34
430	2020 Hindsight: Should evolutionary virologists have expected the unexpected during a pandemic?. <i>Evolution; International Journal of Organic Evolution</i> , 2021, 75, 2311-2316.	1.1	6
431	Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium. <i>MBio</i> , 2021, 12, e0085021.	1.8	27
432	Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve <i>In Vitro</i> to Higher Infectivity through More Efficient Binding to Heparan Sulfate and Reduced S1/S2 Cleavage. <i>Journal of Virology</i> , 2021, 95, e0135721.	1.5	25
433	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
435	Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations. <i>MBio</i> , 2021, 12, e0118821.	1.8	30
436	Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 316.	7.1	17
437	Reducing SARS-CoV-2 pathological protein activity with small molecules. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 383-397.	2.4	11

#	ARTICLE	IF	CITATIONS
438	D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage. <i>MBio</i> , 2021, 12, e0058721.	1.8	34
440	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
441	Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. <i>Biomolecules</i> , 2021, 11, 1273.	1.8	30
442	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	8
443	Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates. <i>Frontiers in Microbiology</i> , 2021, 12, 626553.	1.5	90
445	Possible Use of Phytochemicals for Recovery from COVID-19-Induced Anosmia and Ageusia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8912.	1.8	32
446	M13 Virus Triboelectricity and Energy Harvesting. <i>Nano Letters</i> , 2021, 21, 6851-6858.	4.5	11
448	An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. <i>Turkish Journal of Biology</i> , 2021, 45, 342-357.	2.1	3
449	Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. <i>Nature Communications</i> , 2021, 12, 5135.	5.8	107
450	A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. <i>Antiviral Research</i> , 2021, 192, 105122.	1.9	47
451	Mechanical activation of spike fosters SARS-CoV-2 viral infection. <i>Cell Research</i> , 2021, 31, 1047-1060.	5.7	33
452	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8498.	1.8	11
453	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. <i>Vaccines</i> , 2021, 9, 914.	2.1	20
455	Binding and entering: COVID finds a new home. <i>PLoS Pathogens</i> , 2021, 17, e1009857.	2.1	9
456	COVID-19 and the gain of function debates. <i>EMBO Reports</i> , 2021, 22, e53739.	2.0	3
457	Whole Genome Sequencing of SARS-CoV-2 Strains in COVID-19 Patients From Djibouti Shows Novel Mutations and Clades Replacing Over Time. <i>Frontiers in Medicine</i> , 2021, 8, 737602.	1.2	4
459	Global variation in SARS-CoV-2 proteome and its implication in pre-lockdown emergence and dissemination of 5 dominant SARS-CoV-2 clades. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104973.	1.0	12
460	Superspreading in the emergence of COVID-19 variants. <i>Trends in Genetics</i> , 2021, 37, 1069-1080.	2.9	31

#	ARTICLE	IF	CITATIONS
461	SARS-CoV-2 Transgressing LncRNAs Uncovers the Known Unknowns. <i>Physiological Genomics</i> , 2021, 53, 433-440.	1.0	4
463	Neutral evolution test of the spike protein of SARS-CoV-2 and its implications in the binding to ACE2. <i>Scientific Reports</i> , 2021, 11, 18847.	1.6	13
464	S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 343.	7.1	24
466	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6.	6.6	52
467	Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination. <i>FEBS Letters</i> , 2021, 595, 2366-2382.	1.3	21
469	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 37, 109825.	2.9	73
471	Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. <i>Diagnostics</i> , 2021, 11, 1788.	1.3	8
472	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
473	Serological and viral genetic features of patients with COVID-19 in a selected German patient cohort—correlation with disease characteristics. <i>GeroScience</i> , 2021, 43, 2249-2264.	2.1	4
474	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. <i>Microorganisms</i> , 2021, 9, 1964.	1.6	13
476	The SARS-CoV-2 spike protein is vulnerable to moderate electric fields. <i>Nature Communications</i> , 2021, 12, 5407.	5.8	26
478	Analyzing the effect of mutations in SARS-CoV2 papain-like protease from Saudi isolates on protein structure and drug-protein binding: Molecular modelling and dynamics studies. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 526-533.	1.8	3
479	Application of omics technology to combat the COVID-19 pandemic. <i>MedComm</i> , 2021, 2, 381-401.	3.1	11
480	Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States. <i>Journal of Medical Virology</i> , 2022, 94, 310-317.	2.5	59
481	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
482	Application of polymerase chain reaction-restriction fragment length polymorphism (RFLP-PCR) in the analysis of single nucleotide polymorphisms (SNPs). <i>Acta Universitatis Lodzianis Folia Biologica Et Oecologica</i> , 0, 17, 48-53.	1.0	3
484	Targeted Hybridization Capture of SARS-CoV-2 and Metagenomics Enables Genetic Variant Discovery and Nasal Microbiome Insights. <i>Microbiology Spectrum</i> , 2021, 9, e0019721.	1.2	22
485	Multiplicity of Glycosphingolipid-Enriched Microdomain-Driven Immune Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9565.	1.8	6

#	ARTICLE	IF	CITATIONS
487	Variants of SARS Coronavirus-2 and Their Potential Impact on the Future of the COVID-19 Pandemic. <i>Zoonoses</i> , 2021, 1, .	0.5	3
488	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
489	Synthetic proteins for COVID-19 diagnostics. <i>Peptides</i> , 2021, 143, 170583.	1.2	5
490	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. <i>Nature Medicine</i> , 2021, 27, 1518-1524.	15.2	178
493	Spread of Mink SARS-CoV-2 Variants in Humans: A Model of Sarbecovirus Interspecies Evolution. <i>Frontiers in Microbiology</i> , 2021, 12, 675528.	1.5	35
494	Veterinary Experiences can Inform One Health Strategies for Animal Coronaviruses. <i>EcoHealth</i> , 2021, 18, 301-314.	0.9	1
495	The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. <i>Cell</i> , 2021, 184, 5189-5200.e7.	13.5	186
496	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
497	Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 5654.	5.8	89
498	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
500	SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia. <i>International Journal of Infectious Diseases</i> , 2021, 110, 410-416.	1.5	5
501	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. <i>Viruses</i> , 2021, 13, 1743.	1.5	15
502	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	16
503	Decomposing the sources of SARS-CoV-2 fitness variation in the United States. <i>Virus Evolution</i> , 2021, 7, veab073.	2.2	14
504	Tiled-ClickSeq for targeted sequencing of complete coronavirus genomes with simultaneous capture of RNA recombination and minority variants. <i>ELife</i> , 2021, 10, .	2.8	22
506	D614G mutation in the SARS-CoV-2 spike protein enhances viral fitness by desensitizing it to temperature-dependent denaturation. <i>Journal of Biological Chemistry</i> , 2021, 297, 101238.	1.6	46
507	The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. <i>Nature Genetics</i> , 2021, 53, 1405-1414.	9.4	35
509	Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. <i>Journal of Virology</i> , 2021, 95, e0096621.	1.5	17

#	ARTICLE	IF	CITATIONS
510	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. <i>Cell Discovery</i> , 2021, 7, 82.	3.1	22
512	High Rate of Mutational Events in SARS-CoV-2 Genomes across Brazilian Geographical Regions, February 2020 to June 2021. <i>Viruses</i> , 2021, 13, 1806.	1.5	9
513	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	2.1	12
514	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
515	SARS-CoV-2 viral RNA levels are not 'viral load'. <i>Trends in Microbiology</i> , 2021, 29, 970-972.	3.5	26
516	Case report: change of dominant strain during dual SARS-CoV-2 infection. <i>BMC Infectious Diseases</i> , 2021, 21, 959.	1.3	32
517	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 2893-2907.e5.	6.6	107
518	Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. <i>Cell Reports</i> , 2021, 37, 109771.	2.9	38
519	Temporal Analysis of SARS-CoV-2 Variants during the COVID-19 Pandemic in Nepal. <i>Covid</i> , 2021, 1, 423-434.	0.7	9
521	Vaccines efficacy to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4128-4130.	1.4	1
522	Detection of SARS-CoV-2 spike protein D614G mutation by qPCR-HRM analysis. <i>Heliyon</i> , 2021, 7, e07936.	1.4	10
523	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
524	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
525	Viral whole-genome sequencing to assess impact of universal masking on SARS-CoV-2 transmission among pediatric healthcare workers. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1408-1412.	1.0	4
526	Proteases and variants: context matters for SARS-CoV-2 entry assays. <i>Current Opinion in Virology</i> , 2021, 50, 49-58.	2.6	23
527	Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. <i>Bioorganic Chemistry</i> , 2021, 115, 105196.	2.0	5
528	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. <i>American Journal of Pathology</i> , 2021, 191, 1754-1773.	1.9	26
529	Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains. <i>Virology</i> , 2021, 562, 63-73.	1.1	26

#	ARTICLE	IF	CITATIONS
530	Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells. <i>Antiviral Research</i> , 2021, 194, 105162.	1.9	6
531	dsmCRISPR: Dual synthetic mismatches CRISPR/Cas12a-based detection of SARS-CoV-2 D614G mutation. <i>Virus Research</i> , 2021, 304, 198530.	1.1	23
532	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. <i>Clinical Immunology</i> , 2021, 231, 108804.	1.4	5
533	Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds. <i>Dyes and Pigments</i> , 2021, 194, 109570.	2.0	12
534	No association between the SARS-CoV-2 variants and mortality rates in the Eastern Mediterranean Region. <i>Gene</i> , 2021, 801, 145843.	1.0	4
535	From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic. <i>Environmental Research</i> , 2021, 201, 111555.	3.7	8
536	Comparison of SARS-CoV-2 variant lethality in human angiotensin-converting enzyme 2 transgenic mice. <i>Virus Research</i> , 2021, 305, 198563.	1.1	3
537	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. <i>Virology</i> , 2021, 563, 134-145.	1.1	74
538	COVID-19 in Asia: Transmission factors, re-opening policies, and vaccination simulation. <i>Environmental Research</i> , 2021, 202, 111657.	3.7	28
539	Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. <i>Journal of Autoimmunity</i> , 2021, 124, 102715.	3.0	209
540	Immune response variables and viral mutations impact on COVID-19 reinfection and relapse. <i>International Immunopharmacology</i> , 2021, 100, 108108.	1.7	7
541	Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines. <i>Biochimie</i> , 2021, 191, 91-103.	1.3	7
542	D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin?. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 237-241.	2.3	30
543	Rapid, inexpensive methods for exploring SARS CoV-2 D614G mutation. <i>Meta Gene</i> , 2021, 30, 100950.	0.3	3
544	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931.		18
545	SARS-CoV-2 in residential rooms of two self-isolating persons with COVID-19. <i>Journal of Aerosol Science</i> , 2022, 159, 105870.	1.8	34
546	Preventing Coronavirus Disease 2019 in Kidney Transplant Recipients: Where Should We Begin?. <i>Nephron</i> , 2021, 145, 280-284.	0.9	2
547	Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. <i>Nephron</i> , 2021, 145, 392-403.	0.9	58

#	ARTICLE	IF	CITATIONS
548	COVIDOUTCOME”estimating COVID severity based on mutation signatures in the SARS-CoV-2 genome. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	1.4	17
549	Evolution of SARS-CoV-2 virus and assessment of the effectiveness of COVID-19 vaccine. F1000Research, 0, 10, 28.	0.8	2
551	Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020. Emerging Infectious Diseases, 2021, 27, 1737-1740.	2.0	16
552	Dynamic Network Modeling of Allosteric Interactions and Communication Pathways in the SARS-CoV-2 Spike Trimer Mutants: Differential Modulation of Conformational Landscapes and Signal Transmission via Cascades of Regulatory Switches. Journal of Physical Chemistry B, 2021, 125, 850-873.	1.2	66
554	Multiple detection and spread of novel strains of the SARS-CoV-2 B.1.177 (B.1.177.75) lineage that test negative by a commercially available nucleocapsid gene real-time RT-PCR. Emerging Microbes and Infections, 2021, 10, 1148-1155.	3.0	21
559	Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. Immune Network, 2021, 21, e8.	1.6	3
560	Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. Molecules, 2021, 26, 632.	1.7	22
562	Development and application of therapeutic antibodies against COVID-19. International Journal of Biological Sciences, 2021, 17, 1486-1496.	2.6	47
564	Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerging Microbes and Infections, 2021, 10, 797-809.	3.0	42
565	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerging Microbes and Infections, 2021, 10, 507-535.	3.0	202
566	The emerging SARS-CoV-2 variants of concern. Therapeutic Advances in Infectious Disease, 2021, 8, 2049936121110243.	1.1	82
591	Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection. Biochemistry (Moscow), 2021, 86, 257-261.	0.7	39
592	Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. Journal of Translational Medicine, 2020, 18, 494.	1.8	15
593	Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic. Bulletin of the Chemical Society of Japan, 2021, 94, 1478-1490.	2.0	24
594	Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation. Genes, 2021, 12, 16.	1.0	19
595	Dynamically evolving novel overlapping gene as a factor in the SARS-CoV-2 pandemic. ELife, 2020, 9, .	2.8	74
596	A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. International Journal of Immunopathology and Pharmacology, 2021, 35, 2058738421110501.	1.0	26
597	A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19. Briefings in Bioinformatics, 2022, 23, .	3.2	9

#	ARTICLE	IF	CITATIONS
598	Genetic diversity of SARS-CoV-2 in South America: demographic history and structuration signals. <i>Archives of Virology</i> , 2021, 166, 3357-3371.	0.9	3
599	Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5133-5140.	2.5	21
600	Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2053-2066.	2.7	8
601	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	3.6	42
602	The challenges of COVID-19 Delta variant: Prevention and vaccine development. <i>MedComm</i> , 2021, 2, 846-854.	3.1	37
603	The Rapid Assessment of Aggregated Wastewater Samples for Genomic Surveillance of SARS-CoV-2 on a City-Wide Scale. <i>Pathogens</i> , 2021, 10, 1271.	1.2	15
607	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. <i>Science Advances</i> , 2021, 7, eabj3627.	4.7	24
608	In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. <i>Cell Reports</i> , 2021, 37, 109838.	2.9	8
609	Structure-guided antibody cocktail for prevention and treatment of COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009704.	2.1	12
610	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. <i>MSystems</i> , 2021, 6, e0009521.	1.7	26
611	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
612	Real-time quantification of the transmission advantage associated with a single mutation in pathogen genomes: a case study on the D614G substitution of SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 1039.	1.3	2
613	SARS-CoV-2 variants, a still unfinished story. <i>Vacunas (English Edition)</i> , 2021, 22, 167-173.	0.3	4
614	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review. <i>Clinical Infectious Diseases</i> , 2022, 75, e1195-e1201.	2.9	13
615	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	1.5	29
616	Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants. <i>IScience</i> , 2021, 24, 103329.	1.9	0
617	Genomic Epidemiology of SARS-CoV-2 in Pakistan. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 727-740.	3.0	8
618	Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720357.	1.8	7

#	ARTICLE	IF	CITATIONS
621	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021, 12, 6097.	5.8	38
624	There is no "origin" to SARS-CoV-2. <i>Environmental Research</i> , 2022, 207, 112173.	3.7	16
627	One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. <i>Emerging Microbes and Infections</i> , 2021, 10, 2016-2029.	3.0	12
629	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. <i>Physiology</i> , 2022, 37, 88-100.	1.6	18
630	SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. <i>Journal of Virology</i> , 2022, 96, JVI0151121.	1.5	58
632	Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using in Silico Approach. <i>MBio</i> , 2021, 12, e0268721.	1.8	3
633	Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H. <i>MBio</i> , 2021, 12, e0251021.	1.8	33
634	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	14
635	Introduction of SARS-CoV-2 C.37 (WHO VOI lambda) in the Sao Paulo State, Southeast Brazil. <i>Journal of Medical Virology</i> , 2021, , .	2.5	6
636	Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. <i>Current Medical Science</i> , 2021, 41, 1065.	0.7	3
638	Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 765039.	1.8	43
639	Mutational profile confers increased stability of SARS-CoV-2 spike protein in Brazilian isolates. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13184-13189.	2.0	3
640	Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals. <i>Viruses</i> , 2021, 13, 1993.	1.5	70
641	Evaluation of the clinical and analytical performance of the Seegene allplex [®] SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI). <i>Journal of Clinical Virology</i> , 2021, 144, 104996.	1.6	16
642	Understanding mutation hotspots for the SARS-CoV-2 spike protein using Shannon Entropy and K-means clustering. <i>Computers in Biology and Medicine</i> , 2021, 138, 104915.	3.9	31
643	Self-resetting molecular probes for nucleic acids detection enabled by fuel dissipative systems. <i>Nano Today</i> , 2021, 41, 101308.	6.2	17
644	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
646	An Explorative Tool for Mutation Tracking in the Spike Glycoprotein of SARS-CoV-2. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
647	Genomic Epidemiology Reveals Multiple Introductions of Severe Acute Respiratory Syndrome Coronavirus 2 in Niigata City, Japan, Between February and May 2020. <i>Frontiers in Microbiology</i> , 2021, 12, 749149.	1.5	4
648	Nanopore sequencing of SARS-CoV-2: Comparison of short and long PCR-tiling amplicon protocols. <i>PLoS ONE</i> , 2021, 16, e0259277.	1.1	16
649	QUASISPECIES FEATURE IN SARS-CoV-2. <i>Journal of Experimental Biology and Agricultural Sciences</i> , 2021, 9, 591-597.	0.1	0
650	Dominant clade-featured SARS-CoV-2 co-occurring mutations reveal plausible epistasis: An in silico based hypothetical model. <i>Journal of Medical Virology</i> , 2022, 94, 1035-1049.	2.5	16
651	Virus genomics as a clinical and epidemiological tool. <i>EBioMedicine</i> , 2020, 62, 103141.	2.7	0
657	Voice Series COVID-19 Special Collection Part 1: Interview with clinicians: COVID-19 mutation and current breakthrough in vaccine development. <i>BIO Integration</i> , 2021, 2, .	0.9	0
659	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <i>Vaccine</i> , 2021, 39, 7394-7400.	1.7	63
660	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
661	Analysis of SARS-COV2 spike protein variants among Iraqi isolates. <i>Gene Reports</i> , 2022, 26, 101420.	0.4	12
662	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
663	Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption. <i>PLoS Pathogens</i> , 2021, 17, e1010053.	2.1	43
664	Identification of genotypic variants and its proteomic mutations of Brazilian SARS-CoV-2 isolates. <i>Virus Research</i> , 2022, 307, 198618.	1.1	5
665	Predominance of SARS-CoV-2 P.1 (Gamma) lineage inducing the recent COVID-19 wave in southern Brazil and the finding of an additional S: D614A mutation. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105134.	1.0	11
667	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
668	Lineage Divergence and Vector-Specific Adaptation Have Driven Chikungunya Virus onto Multiple Adaptive Landscapes. <i>MBio</i> , 2021, 12, e0273821.	1.8	8
669	Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom's first national lockdown. <i>Scientific Reports</i> , 2021, 11, 21484.	1.6	7
670	SARS-CoV-2 Among Military and Civilian Patients, Metro Manila, Philippines. <i>Military Medicine</i> , 2021, 186, e760-e766.	0.4	2
671	Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation. <i>Hawai'i Journal of Health & Social Welfare</i> , 2021, 80, 52-61.	0.2	25

#	ARTICLE	IF	CITATIONS
672	Coronavirus Disease Update on Epidemiology, Virology, and Prevention. Compendium of Continuing Education in Dentistry (Jamesburg, NJ: 1995), 2021, 42, 280-289.	0.1	0
673	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. SSRN Electronic Journal, 0, , .	0.4	4
674	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Theranostics, 2022, 12, 1-17.	4.6	6
675	Cross-sectional genomic perspective of epidemic waves of SARS-CoV-2: A pan India study. Virus Research, 2022, 308, 198642.	1.1	8
676	Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage. Virus Research, 2022, 308, 198629.	1.1	6
677	Molecular Epidemiological Insights into Transmission Trends in Nagoya Area Based on SARS-CoV-2 Genome Sequencing (Mar-Oct, 2020). Journal of the Japanese Association for Infectious Diseases, 2021, 95, 293-300.	0.0	0
678	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. Applied Microbiology and Biotechnology, 2021, 105, 9035-9045.	1.7	34
679	Studies on Growth Characteristics and Cross-Neutralization of Wild-Type and Delta SARS-CoV-2 From Hisar (India). Frontiers in Cellular and Infection Microbiology, 2021, 11, 771524.	1.8	5
680	Exposing structural variations in SARS-CoV-2 evolution. Scientific Reports, 2021, 11, 22042.	1.6	6
681	PD-1 blockade counteracts post-“COVID-19 immune abnormalities and stimulates the anti-“SARS-CoV-2 immune response. JCI Insight, 2021, 6, .	2.3	51
682	Association of cardiac injury with hypertension in hospitalized patients with COVID-19 in China. Scientific Reports, 2021, 11, 22389.	1.6	4
684	The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature, 2022, 602, 294-299.	13.7	364
685	Underlying selection for the diversity of spike protein sequences of SARS-CoV-2. IUBMB Life, 2022, 74, 213-220.	1.5	4
686	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. Archives of Virology, 2022, 167, 293-305.	0.9	28
687	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. Viruses, 2021, 13, 2295.	1.5	13
689	Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations. JCI Insight, 2021, 6, .	2.3	21
690	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. Vaccines, 2021, 9, 1409.	2.1	22
691	Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2. FEBS Open Bio, 2022, 12, 285-294.	1.0	20

#	ARTICLE	IF	CITATIONS
692	TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction. PLoS Pathogens, 2021, 17, e1009820.	2.1	13
693	Age-Related Susceptibility of Ferrets to SARS-CoV-2 Infection. Journal of Virology, 2022, 96, JVI0145521.	1.5	16
694	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. Frontiers in Immunology, 2021, 12, 771242.	2.2	15
695	Progress in the Diagnosis and Treatment of COVID-19 in Children: A Review. International Journal of General Medicine, 2021, Volume 14, 8097-8108.	0.8	10
696	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. Microbiology Spectrum, 2021, 9, e0109621.	1.2	39
698	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. Med, 2021, 2, 1327-1341.e4.	2.2	31
699	Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host and Microbe, 2021, 29, 1788-1801.e6.	5.1	145
700	Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature, 2022, 602, 300-306.	13.7	428
701	Hematological changes associated with COVID-19 infection. Journal of Clinical Laboratory Analysis, 2022, 36, e24064.	0.9	31
703	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. MBio, 2021, 12, e0231521.	1.8	6
704	Re-emergence of Gamma-like-II and emergence of Gamma-S:E661D SARS-CoV-2 lineages in the south of Brazil after the 2021 outbreak. Virology Journal, 2021, 18, 222.	1.4	8
705	Codon usage, phylogeny and binding energy estimation predict the evolution of SARS-CoV-2. One Health, 2021, 13, 100352.	1.5	2
706	Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States. Transfusion, 2022, 62, 483-492.	0.8	2
707	SARS-CoV-2 Variants: Past, Present and Future. Economics, Law, and Institutions in Asia Pacific, 2022, , 3-23.	0.4	0
708	Transmission dynamics and successful control measures of SARS-CoV-2 in the mega-size city of Guangzhou, China. Medicine (United States), 2021, 100, e27846.	0.4	7
709	Comparison of SARS-CoV-2 neutralizing antibody testing of convalescent plasma donations in the Netherlands and England: A pilot study. Health Science Reports, 2021, 4, e439.	0.6	0
710	COVID-19 variants that escape vaccine immunity: Global and Indian context—are more vaccines needed?. Journal of Biosciences, 2021, 46, 1.	0.5	2
711	SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. IScience, 2021, 24, 103467.	1.9	26

#	ARTICLE	IF	CITATIONS
713	An overview of the ongoing challenges in SARS-CoV-2 global control. German Journal of Microbiology, 2021, 1, 1-18.	0.3	17
714	Inferring the stabilization effects of SARS-CoV-2 variants on the binding with ACE2 receptor. Communications Biology, 2022, 5, 1421.	2.0	19
715	Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles. Biosafety and Health, 2022, 4, 38-44.	1.2	7
716	Mutational and phylogenetic analyses of the two lineages of the Omicron variant. Journal of Medical Virology, 2022, 94, 1777-1779.	2.5	68
717	Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cellular and Molecular Immunology, 2022, 19, 293-295.	4.8	175
718	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mutational Pattern in the Fourth Pandemic Phase in Greece. Current Issues in Molecular Biology, 2022, 44, 329-335.	1.0	3
719	Iron dysregulation in COVID-19 and reciprocal evolution of SARS-CoV-2: Natura nihil frustra facit. Journal of Cellular Biochemistry, 2022, 123, 601-619.	1.2	21
720	Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India. Archives of Virology, 2022, 167, 393-403.	0.9	5
721	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. Applied Sciences (Switzerland), 2022, 12, 665.	1.3	8
722	Two-step fitness selection for intra-host variations in SARS-CoV-2. Cell Reports, 2022, 38, 110205.	2.9	38
723	Rapid and accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform. Biosensors and Bioelectronics, 2022, 198, 113857.	5.3	31
724	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. Gene, 2022, 813, 146113.	1.0	8
725	Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical Specimens. SSRN Electronic Journal, 0, , .	0.4	0
726	Requirements for a Bespoke Intensive Care Unit Dashboard in Response to the COVID-19 Pandemic: Semistructured Interview Study. JMIR Human Factors, 2022, 9, e30523.	1.0	6
727	Fast forward evolution in real time: the rapid spread of SARS-CoV-2 variant of concern lineage B.1.1.7 in Saxony-Anhalt over a period of 5 months. Laboratoriums Medizin, 2022, 46, 71-75.	0.1	3
728	N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry. Scientific Reports, 2021, 11, 23561.	1.6	14
730	Whole genome amplicon sequencing and phylogenetic analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from lineage B.1.36.27 isolated in Hong Kong. Expert Review of Molecular Diagnostics, 2021, , 1-6.	1.5	2
732	Conformational Flexibility and Local Frustration in the Functional States of the SARS-CoV-2 Spike B.1.1.7 and B.1.351 Variants: Mutation-Induced Allosteric Modulation Mechanism of Functional Dynamics and Protein Stability. International Journal of Molecular Sciences, 2022, 23, 1646.	1.8	2

#	ARTICLE	IF	CITATIONS
733	mRNA-1273 and Ad26.COVS Vaccines Protect Against the B.1.621 Variant of SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	0
734	Recent advances and clinical application in point-of-care testing of SARS-CoV-2. Journal of Medical Virology, 2022, 94, 1866-1875.	2.5	21
735	A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2. Archiv Der Pharmazie, 2022, 355, e2100382.	2.1	4
736	Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	28
737	SARS-CoV-2 Virology. Infectious Disease Clinics of North America, 2022, 36, 251-265.	1.9	7
738	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. RSC Medicinal Chemistry, 2022, 13, 647-675.	1.7	3
739	Discriminatory Weight of SNPs in Spike SARS-CoV-2 Variants: A Technically Rapid, Unambiguous, and Bioinformatically Validated Laboratory Approach. Viruses, 2022, 14, 123.	1.5	0
740	Genomic Characterization of SARS-CoV-2 Isolated from Patients with Distinct Disease Outcomes in Mexico. Microbiology Spectrum, 2022, , e0124921.	1.2	5
741	Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2. Royal Society Open Science, 2022, 9, 211021.	1.1	8
742	Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo. Nature Microbiology, 2022, 7, 213-223.	5.9	45
744	The "LLQY" motif on SARS-CoV-2 spike protein affects S incorporation into virus particles. Journal of Virology, 2022, , jvi0189721.	1.5	1
745	SARS-CoV-2 omicron variant: Could it be another threat?. Journal of Medical Virology, 2022, 94, 1284-1288.	2.5	24
746	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. Journal of Allergy and Clinical Immunology, 2022, 149, 1242-1252.e12.	1.5	23
747	Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. Vaccine, 2022, 40, 1289-1298.	1.7	9
748	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Cell Reports, 2022, 38, 110218.	2.9	148
749	The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour. Computational and Structural Biotechnology Journal, 2022, 20, 139-147.	1.9	19
750	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692.	13.7	475
751	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. International Journal of Biological Sciences, 2022, 18, 459-472.	2.6	65

#	ARTICLE	IF	CITATIONS
752	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
753	The Effect of Sanitizing Treatments on Respirator Filtration Performance. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 641.	1.2	3
754	Critical Mutations of the SARS-CoV-2 Virus. <i>WSEAS Transactions on Biology and Biomedicine</i> , 2022, 19, 22-30.	0.3	1
756	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 8-19.	2.5	5
757	Ex Vivo and in Vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors. <i>Molecular Therapy</i> , 2022, 30, 2005-2023.	3.7	10
758	Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. <i>Emerging Microbes and Infections</i> , 2022, 11, 567-572.	3.0	39
759	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. <i>Cell Host and Microbe</i> , 2022, 30, 373-387.e7.	5.1	138
761	Developing an Amplification Refractory Mutation System-Quantitative Reverse Transcription-PCR Assay for Rapid and Sensitive Screening of SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2022, 10, e0143821.	1.2	11
763	Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. <i>Journal of Infection and Public Health</i> , 2022, 15, 42-50.	1.9	3
764	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
765	SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review. <i>Life</i> , 2022, 12, 170.	1.1	39
766	Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. <i>Cell Reports</i> , 2022, 38, 110348.	2.9	14
768	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. <i>BMC Molecular and Cell Biology</i> , 2022, 23, 2.	1.0	10
770	Designing Post COVID-19 Buildings: Approaches for Achieving Healthy Buildings. <i>Buildings</i> , 2022, 12, 74.	1.4	46
771	Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12179.	5.5	24
773	The Emergence of SARS-CoV-2 Variants of Concern Is Driven by Acceleration of the Substitution Rate. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	78
775	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
777	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55

#	ARTICLE	IF	CITATIONS
778	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 267-293.	1.9	10
779	SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. <i>Nature</i> , 2022, 603, 715-720.	13.7	577
780	Variant analysis of SARS-CoV-2 strains with phylogenetic analysis and the Coronavirus Antiviral and Resistance Database. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 157-167.	0.6	2
781	Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00922.	1.1	20
782	BepiTBR: T-B reciprocity enhances B cell epitope prediction. <i>IScience</i> , 2022, 25, 103764.	1.9	9
783	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. <i>Journal of Infection and Public Health</i> , 2022, 15, 277-288.	1.9	21
784	Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India. <i>Microbial Pathogenesis</i> , 2022, 164, 105404.	1.3	14
785	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	5.8	23
786	Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 821664.	2.2	22
787	Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. <i>Nature Communications</i> , 2022, 13, 852.	5.8	92
788	Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations. <i>Cell Reports Methods</i> , 2022, 2, 100173.	1.4	12
790	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. <i>Wellcome Open Research</i> , 0, 6, 110.	0.9	4
791	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. <i>Cell</i> , 2022, 185, 447-456.e11.	13.5	736
792	SARS-CoV-2 Variants and Vaccination. <i>Zoonoses</i> , 2022, 2, .	0.5	16
793	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	1.9	6
794	Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19. <i>Viruses</i> , 2022, 14, 353.	1.5	11
795	Wastewater surveillance for SARS-CoV-2 in a small coastal community: Effects of tourism on viral presence and variant identification among low prevalence populations. <i>Environmental Research</i> , 2022, 208, 112496.	3.7	16
796	Preparation for the challenge of heavily mutated Omicron variant. <i>Clinical and Translational Medicine</i> , 2021, 11, e679.	1.7	19

#	ARTICLE	IF	CITATIONS
797	SARS-CoV-2 Omicron variant: Characteristics and prevention. <i>MedComm</i> , 2021, 2, 838-845.	3.1	364
798	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
799	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	2.3	112
800	Using thermodynamic equilibrium models to predict the effect of antiviral agents on infectivity: Theoretical application to SARS-CoV-2 and other viruses.. <i>Microbial Risk Analysis</i> , 2022, 21, 100198.	1.3	17
801	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 0, , .	13.7	101
802	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021, 6, 146.	2.9	14
803	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	13.7	249
804	Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. <i>Nature</i> , 2022, 602, 307-313.	13.7	79
805	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	13.7	917
806	SARS-CoV-2 spreads through cell-to-cell transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	145
816	Rapid assessment of SARS-CoV-2-evolved variants using virus-like particles. <i>Science</i> , 2021, 374, 1626-1632.	6.0	216
817	SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection. <i>PLoS Pathogens</i> , 2021, 17, e1010175.	2.1	15
818	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29
819	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. <i>Viruses</i> , 2021, 13, 2485.	1.5	23
820	SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF- κ B pathway. <i>ELife</i> , 2021, 10, .	2.8	215
823	Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12.		4
824	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	5.8	13
825	COVID-19 variants that escape vaccine immunity: Global and Indian context-are more vaccines needed?. <i>Journal of Biosciences</i> , 2021, 46, .	0.5	0

#	ARTICLE	IF	CITATIONS
826	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
827	Significance of the RBD mutations in the SARS-CoV-2 omicron: from spike opening to antibody escape and cell attachment. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 9123-9129.	1.3	24
828	Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm. <i>Genetics and Molecular Biology</i> , 2022, 45, e20210309.	0.6	8
829	An Unsupervised Clustering Algorithm to Cluster the New SARS-CoV-2 Virus Mutation. <i>Lecture Notes in Networks and Systems</i> , 2022, , 173-181.	0.5	2
830	Unrecognized introductions of SARS-CoV-2 into the US state of Georgia shaped the early epidemic. <i>Virus Evolution</i> , 2022, 8, veac011.	2.2	2
831	Tetra-primer ARMS-PCR combined with dual-color fluorescent lateral flow assay for the discrimination of SARS-CoV-2 and its mutations with a handheld wireless reader. <i>Lab on A Chip</i> , 2022, 22, 1531-1541.	3.1	15
833	High diversity in Delta variant across countries revealed by genome-wide analysis of SARS-CoV-2 beyond the Spike protein. <i>Molecular Systems Biology</i> , 2022, 18, e10673.	3.2	18
834	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
836	Fast Evaluation of Viral Emerging Risks (FEVER): A computational tool for biosurveillance, diagnostics, and mutation typing of emerging viral pathogens. <i>PLOS Global Public Health</i> , 2022, 2, e0000207.	0.5	1
838	Evolutionary dynamics of SARS-CoV-2 circulating in Yogyakarta and Central Java, Indonesia: sequence analysis covering furin cleavage site (FCS) region of the spike protein. <i>International Microbiology</i> , 2022, 25, 531-540.	1.1	2
839	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 485-488.e3.	5.1	80
840	A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity. <i>Frontiers in Immunology</i> , 2022, 13, 837443.	2.2	4
841	Population Genomics Approaches for Genetic Characterization of SARS-CoV-2 Lineages. <i>Frontiers in Medicine</i> , 2022, 9, 826746.	1.2	7
842	Whole genome sequence analysis showing unique SARS-CoV-2 lineages of B.1.524 and AU.2 in Malaysia. <i>PLoS ONE</i> , 2022, 17, e0263678.	1.1	8
845	An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. <i>Npj Vaccines</i> , 2022, 7, 24.	2.9	18
846	Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2172.	1.8	5
847	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7
849	COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development. <i>Microorganisms</i> , 2022, 10, 598.	1.6	14

#	ARTICLE	IF	CITATIONS
850	Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein. <i>MBio</i> , 2022, 13, e0203021.	1.8	10
851	Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2928.	1.8	8
853	The dynamics of circulating SARS-CoV-2 lineages in Bogor and surrounding areas reflect variant shifting during the first and second waves of COVID-19 in Indonesia. <i>PeerJ</i> , 2022, 10, e13132.	0.9	9
854	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. <i>Cell</i> , 2022, 185, 1572-1587.e11.	13.5	71
856	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. <i>Frontiers in Immunology</i> , 2022, 13, 836232.	2.2	15
857	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. <i>Frontiers in Immunology</i> , 2022, 13, 861050.	2.2	8
859	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
860	An Upgrade on the Surveillance System of SARS-CoV-2: Deployment of New Methods for Genetic Inspection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3143.	1.8	2
861	Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission. <i>PLoS Pathogens</i> , 2022, 18, e1010181.	2.1	15
862	The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model. <i>Communications Biology</i> , 2022, 5, 225.	2.0	10
863	Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. <i>MBio</i> , 2022, 13, e0009922.	1.8	22
864	Association between COVID-19 Diagnosis and Coronary Artery Thrombosis: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 702.	1.4	15
865	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
866	Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic. <i>Genes</i> , 2022, 13, 552.	1.0	13
867	Role of the Microbiome in the Pathogenesis of COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 736397.	1.8	17
868	Adopting Natural Host Immune Response Against Zoonosis. <i>Journal of Education, Management and Development Studies</i> , 2022, 2, 52-66.	0.2	0
869	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
870	Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864.	0.4	5

#	ARTICLE	IF	CITATIONS
871	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. <i>Science Translational Medicine</i> , 2022, 14, eabn8057.	5.8	150
872	Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters. <i>Viruses</i> , 2022, 14, 596.	1.5	6
873	Split T7 promoter-based isothermal transcription amplification for one-step fluorescence detection of SARS-CoV-2 and emerging variants. <i>Biosensors and Bioelectronics</i> , 2022, 208, 114221.	5.3	31
875	The Runaway Evolution of SARS-CoV-2 Leading to the Highly Evolved Delta Strain. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	14
877	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. <i>F1000Research</i> , 0, 11, 353.	0.8	1
878	Global trends in COVID-19. , 2022, 1, 31-39.		8
879	Evolutionary history and introduction of SARS-CoV-2 Alpha VOC/B.1.1.7 in Pakistan through international travelers. <i>Virus Evolution</i> , 2022, 8, veac020.	2.2	8
880	Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives. <i>Journal of Drug Targeting</i> , 2022, , 1-11.	2.1	5
881	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
882	Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) including Variant Analysis by Mass Spectrometry in Placental Tissue. <i>Viruses</i> , 2022, 14, 604.	1.5	2
883	Detection and quantification of infectious severe acute respiratory coronavirus-2 in diverse clinical and environmental samples. <i>Scientific Reports</i> , 2022, 12, 5418.	1.6	38
884	Profiling of SARS-CoV-2 Subgenomic RNAs in Clinical Specimens. <i>Microbiology Spectrum</i> , 2022, 10, e0018222.	1.2	13
885	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 38, 110558.	2.9	15
886	High-Integrity Sequencing of Spike Gene for SARS-CoV-2 Variant Determination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3257.	1.8	4
887	Conservation and Enhanced Binding of SARS-CoV-2 Omicron Spike Protein to Coreceptor Neuropilin-1 Predicted by Docking Analysis. <i>Infectious Disease Reports</i> , 2022, 14, 243-249.	1.5	17
891	Omicron: Understanding the latest variant of SARS-CoV-2 and strategies for tackling the infection. <i>ChemBioChem</i> , 2022, , .	1.3	4
892	Ultrasensitive Electrochemical Detection of Mutated Viral RNAs with Single-Nucleotide Resolution Using a Nanoporous Electrode Array (NPEA). <i>ACS Nano</i> , 2022, 16, 5764-5777.	7.3	20
893	Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 227.	2.4	20

#	ARTICLE	IF	CITATIONS
894	Dynamic Ca ²⁺ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. <i>Cell Reports</i> , 2022, 39, 110694.	2.9	19
895	Genetic Surveillance of Five SARS-CoV-2 Clinical Samples in Henan Province Using Nanopore Sequencing. <i>Frontiers in Immunology</i> , 2022, 13, 814806.	2.2	5
896	The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico. <i>Microbiology Spectrum</i> , 2022, 10, e0224021.	1.2	21
897	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity. <i>Emerging Microbes and Infections</i> , 2022, 11, 1024-1036.	3.0	5
898	Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allostery as Energetic Drivers of Highly Transmissible Spike Variants. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 1956-1978.	2.5	5
899	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
900	Simple Formulae, Deep Learning and Elaborate Modelling for the COVID-19 Pandemic. <i>Encyclopedia</i> , 2022, 2, 679-689.	2.4	1
901	The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125.	3.6	41
902	Development of colorimetric sensors based on gold nanoparticles for SARS-CoV-2 RdRp, E and S genes detection. <i>Talanta</i> , 2022, 243, 123393.	2.9	19
903	Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity. <i>Metabolism: Clinical and Experimental</i> , 2022, 131, 155181.	1.5	3
904	A comprehensive evolutionary and epidemiological characterization of insertion and deletion mutations in SARS-CoV-2 genomes. <i>Virus Evolution</i> , 2021, 7, veab104.	2.2	9
905	Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo. <i>Science China Life Sciences</i> , 2022, 65, 1181-1197.	2.3	16
906	Clinical, Virological, Immunological, and Genomic Characterization of Asymptomatic and Symptomatic Cases With SARS-CoV-2 Infection in India. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 725035.	1.8	11
907	Emerging SARS-CoV-2 Genotypes Show Different Replication Patterns in Human Pulmonary and Intestinal Epithelial Cells. <i>Viruses</i> , 2022, 14, 23.	1.5	16
908	Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	9
909	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3
912	Antigenic characterization of influenza and SARS-CoV-2 viruses. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2841-2881.	1.9	11
914	SARS-CoV-2 Variant Screening Using a Virus-Receptor-Based Electrical Biosensor. <i>Nano Letters</i> , 2022, 22, 50-57.	4.5	28

#	ARTICLE	IF	CITATIONS
915	Analysis of Clinical Characteristics and Virus Strains Variation of Patients Infected With SARS-CoV-2 in Jiangsu Province—A Retrospective Study. <i>Frontiers in Public Health</i> , 2021, 9, 791600.	1.3	7
916	Semi-Supervised Pipeline for Autonomous Annotation of SARS-CoV-2 Genomes. <i>Viruses</i> , 2021, 13, 2426.	1.5	5
917	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
919	Predicting death from COVID-19 using pre-existing conditions: implications for vaccination triage. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001016.	1.2	1
920	Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice. <i>Veterinary Pathology</i> , 2022, 59, 613-626.	0.8	37
921	Establishment and evaluation of a 30-minute detection method for SARS-CoV-2 nucleic acid using a novel ultra-fast real-time PCR instrument. <i>Journal of Thoracic Disease</i> , 2021, 13, 6866-6875.	0.6	6
922	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
923	The twin-beginnings of COVID-19 in Asia and Europe—one prevails quickly. <i>National Science Review</i> , 2022, 9, nwab223.	4.6	22
924	SARS-CoV-2 spike engagement of ACE2 primes S2â€² site cleavage and fusion initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	60
925	Emerging Coronavirus Mutant - The Delta Plus: A Review. , 2021, 3, 35-42.		0
927	Evolution of enhanced innate immune evasion by SARS-CoV-2. <i>Nature</i> , 2022, 602, 487-495.	13.7	237
933	Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4376.	1.8	16
934	SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1925-1934.	1.9	16
935	Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India. <i>Infection, Genetics and Evolution</i> , 2022, 101, 105282.	1.0	7
936	mRNA-1273 and Ad26.COVS vaccines protect against the B.1.621 variant of SARS-CoV-2. <i>Med</i> , 2022, 3, 309-324.e6.	2.2	6
937	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827.	1.5	14
938	COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response. <i>Biochem</i> , 2022, 2, 115-144.	0.5	1
939	The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan. <i>MBio</i> , 2022, 13, e0068322.	1.8	17

#	ARTICLE	IF	CITATIONS
940	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
941	Development of antibody resistance in emerging mutant strains of SARS CoVâ€²: Impediment for COVIDâ€™19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
942	Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 1871-1887.	1.1	23
944	Wastewater and marine bioindicators surveillance to anticipate COVID-19 prevalence and to explore SARS-CoV-2 diversity by next generation sequencing: One-year study. <i>Science of the Total Environment</i> , 2022, 833, 155140.	3.9	13
945	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
946	SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.. <i>Acta Biomedica</i> , 2022, 93, e2022018.	0.2	0
947	Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2. <i>Methods in Molecular Biology</i> , 2022, 2452, 361-378.	0.4	1
948	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
949	Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 387-394.	1.5	29
950	Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. <i>Virology Journal</i> , 2022, 19, 76.	1.4	61
951	Phylogenetic and genome-wide mutational analysis of SARS-CoV-2 strains circulating in Nigeria: no implications for attenuated COVID-19 outcomes. <i>Osong Public Health and Research Perspectives</i> , 2022, 13, 101-113.	0.7	0
952	Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1093-1102.e3.	5.1	114
953	Photonics enabled intelligence system to identify SARS-CoV 2 mutations. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 3321-3336.	1.7	11
954	Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series. <i>Frontiers in Public Health</i> , 2022, 10, 875558.	1.3	3
956	Biomechanical Dependence of SARS-CoV-2 Infections. <i>ACS Applied Bio Materials</i> , 2022, 5, 2307-2315.	2.3	1
957	Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. <i>Cell Reports</i> , 2022, 39, 110829.	2.9	214
958	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	2.9	287
959	Microbiome Analysis Using Next-Generation Sequencing in Urinary Tract Infections. <i>Urogenital Tract Infection</i> , 2022, 17, 1-7.	0.1	1

#	ARTICLE	IF	CITATIONS
960	Clinical evaluation of the GSD NovaPrime [®] SARS-CoV-2 RTq-PCR assay. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, , 115718.	0.8	0
961	SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	15
962	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
963	Rampant C-to-U deamination accounts for the intrinsically high mutation rate in SARS-CoV-2 spike gene. <i>Rna</i> , 2022, 28, 917-926.	1.6	24
964	Source terms for benchmarking models of SARS-CoV-2 transmission via aerosols and droplets. <i>Royal Society Open Science</i> , 2022, 9, 212022.	1.1	8
965	Can we succeed in the fight against SARS-CoV-2 with its emerging new variants?. <i>Current Pharmaceutical Design</i> , 2022, 28, .	0.9	1
966	Genome sequencing and analysis of genomic diversity in the locally transmitted SARS-CoV-2 in Pakistan. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	3
967	Phylogenetic and amino acid signature analysis of the SARS-CoV-2s lineages circulating in Tunisia. <i>Infection, Genetics and Evolution</i> , 2022, , 105300.	1.0	1
968	Emerging SARS-CoV-2 variants: Why, how, and what's next?., 2022, 1, 100029.		26
969	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
970	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
971	The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2. <i>Pathogens</i> , 2022, 11, 538.	1.2	4
972	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. <i>Vaccines</i> , 2022, 10, 755.	2.1	13
973	Drug repurposing for the treatment of COVID-19. <i>Journal of Pharmacological Sciences</i> , 2022, 149, 108-114.	1.1	12
974	Evolution and Epidemiology of SARS-CoV-2 Virus. <i>Methods in Molecular Biology</i> , 2022, 2452, 3-18.	0.4	0
975	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 2674.	5.8	26
976	The third international hackathon for applying insights into large-scale genomic composition to use cases in a wide range of organisms. <i>F1000Research</i> , 0, 11, 530.	0.8	1
977	Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of selected mutations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3110-3128.	2.0	1

#	ARTICLE	IF	CITATIONS
980	Deep phylogenetic-based clustering analysis uncovers new and shared mutations in SARS-CoV-2 variants as a result of directional and convergent evolution. <i>PLoS ONE</i> , 2022, 17, e0268389.	1.1	7
982	Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America. <i>Global Health, Epidemiology and Genomics</i> , 2022, 2022, 1-9.	0.2	4
983	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
984	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. <i>Cell</i> , 2022, 185, 2279-2291.e17.	13.5	25
986	The ORF8 Protein of SARS-CoV-2 Modulates the Spike Protein and Its Implications in Viral Transmission. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	14
987	SARS-CoV-2 Within-Host and in vitro Genomic Variability and Sub-Genomic RNA Levels Indicate Differences in Viral Expression Between Clinical Cohorts and in vitro Culture. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	4
988	Geographical distribution of SARS-CoV-2 amino acids mutations and the concomitant evolution of seven distinct clades in non-human hosts. <i>Zoonoses and Public Health</i> , 2022, 69, 816-825.	0.9	4
989	Prediction of the effects of the top 10 nonsynonymous variants from 30229 SARS-CoV-2 strains on their proteins. <i>F1000Research</i> , 0, 11, 9.	0.8	3
992	Nanomechanical assay for ultrasensitive and rapid detection of SARS-CoV-2 based on peptide nucleic acid. <i>Nano Research</i> , 2023, 16, 1183-1195.	5.8	6
993	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
995	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
996	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	24
997	Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from bats. <i>Cell Reports</i> , 2022, 39, 110969.	2.9	29
998	Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate. <i>Vaccines</i> , 2022, 10, 897.	2.1	5
999	Mutations of the SARS-CoV-2 Spike Glycoprotein Detected in Cats and Their Effect on Its Structure and Function. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	4
1000	Variant-driven early warning via unsupervised machine learning analysis of spike protein mutations for COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	17
1001	Inactivation of SARS-CoV-2 by charged particles for Future Vaccine Production Applications: A Monte Carlo study. <i>Radiation Physics and Chemistry</i> , 2022, 198, 110265.	1.4	0
1003	Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants. <i>Theranostics</i> , 2022, 12, 4779-4790.	4.6	9

#	ARTICLE	IF	CITATIONS
1004	The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. <i>Vaccines</i> , 2022, 10, 864.	2.1	17
1006	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
1007	SARS-CoV-2 Spike mutations modify the interaction between virus Spike and human ACE2 receptors. <i>Biochemical and Biophysical Research Communications</i> , 2022, 620, 8-14.	1.0	3
1009	Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system. <i>Epidemiology and Infection</i> , 2022, 150, .	1.0	0
1010	SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	73
1012	Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. <i>PLoS Pathogens</i> , 2022, 18, e1010627.	2.1	85
1013	Smartphone-Based SARS-CoV-2 and Variants Detection System using Colorimetric DNAzyme Reaction Triggered by Loop-Mediated Isothermal Amplification (LAMP) with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). <i>ACS Nano</i> , 2022, 16, 11300-11314.	7.3	48
1014	Severe acute respiratory syndrome coronavirus 2 variantsâ€“Possibility of universal vaccine design: A review. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3533-3544.	1.9	3
1015	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
1016	Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6394.	1.8	17
1017	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. <i>Science</i> , 2022, 377, 428-433.	6.0	113
1018	Attacking the SARS-CoV-2 replication machinery with the Pathogen Boxâ€™s molecules. <i>Letters in Drug Design and Discovery</i> , 2022, 19, .	0.4	0
1019	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	63
1020	The Impact of COVID-19 Pandemic on Seafood Safety and Human Health. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
1021	Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021â€“2022. <i>Viruses</i> , 2022, 14, 1297.	1.5	41
1022	Full-genome sequencing and mutation analysis of SARS-CoV-2 isolated from Makassar, South Sulawesi, Indonesia. <i>PeerJ</i> , 0, 10, e13522.	0.9	3
1023	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-inÂ®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. <i>EClinicalMedicine</i> , 2022, 50, 101526.	3.2	20
1024	Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion. <i>Virology</i> , 2022, 573, 84-95.	1.1	1

#	ARTICLE	IF	CITATIONS
1025	Understanding the mutational frequency in SARS-CoV-2 proteome using structural features. <i>Computers in Biology and Medicine</i> , 2022, 147, 105708.	3.9	6
1026	Frustration-driven allosteric regulation and signal transmission in the SARS-CoV-2 spike omicron trimer structures: a crosstalk of the omicron mutation sites allosterically regulates tradeoffs of protein stability and conformational adaptability. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	9
1027	Ongoing Positive Selection Drives the Evolution of SARS-CoV-2 Genomes. <i>Genomics, Proteomics and Bioinformatics</i> , 2022, 20, 1214-1223.	3.0	9
1028	The nervous system during COVID-19: Caught in the crossfire. <i>Immunological Reviews</i> , 2022, 311, 90-111.	2.8	9
1029	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
1030	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
1031	Evidence for selection on SARS-CoV-2 RNA translation revealed by the evolutionary dynamics of mutations in UTRs and CDSs. <i>RNA Biology</i> , 2022, 19, 866-876.	1.5	17
1032	Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro. <i>Journal of Infectious Diseases</i> , 2023, 227, 202-205.	1.9	10
1033	Genomic surveillance of SARS-CoV-2 in patients presenting neurological manifestations. <i>PLoS ONE</i> , 2022, 17, e0270024.	1.1	2
1034	The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation. <i>PLoS Pathogens</i> , 2022, 18, e1010631.	2.1	11
1035	Analysis of the docking property of host variants of hACE2 for SARS-CoV-2 in a large cohort. <i>PLoS Computational Biology</i> , 2022, 18, e1009834.	1.5	1
1036	SARS-CoV-2 Amino Acid Mutations Detection in Greek Patients Infected in the First Wave of the Pandemic. <i>Microorganisms</i> , 2022, 10, 1430.	1.6	0
1037	SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model. <i>Vaccines</i> , 2022, 10, 1104.	2.1	4
1038	A comprehensive review on Covid-19 Omicron (B.1.1.529) variant. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 103372.	1.8	15
1039	Integrating Conformational Dynamics and Perturbation-Based Network Modeling for Mutational Profiling of Binding and Allostery in the SARS-CoV-2 Spike Variant Complexes with Antibodies: Balancing Local and Global Determinants of Mutational Escape Mechanisms. <i>Biomolecules</i> , 2022, 12, 964.	1.8	0
1040	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
1041	COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53.	5.0	43
1042	Rapid and Affordable High Throughput Screening of SARS-CoV-2 Variants Using Denaturing High-Performance Liquid Chromatography Analysis. <i>Frontiers in Virology</i> , 0, 2, .	0.7	0

#	ARTICLE	IF	CITATIONS
1043	Viral isolation allows characterization of early samples of SARS-CoV-2 lineage B.1.1.33 with unique mutations (S: H655Y and T63N) circulating in Southern Brazil in 2020. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1313-1319.	0.8	2
1044	A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant. <i>Journal of Virology</i> , 2022, 96, .	1.5	2
1045	The Impact of D614G Mutation of SARS-COV-2 on the Efficacy of Anti-viral Drugs: A Comparative Molecular Docking and Molecular Dynamics Study. <i>Current Microbiology</i> , 2022, 79, .	1.0	36
1046	Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. <i>Cell</i> , 2022, 185, 2936-2951.e19.	13.5	47
1047	RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
1048	COVID-19: Clinical, Immunological, and Image Findings from Infection to Post-COVID Syndrome. , 2022, , 76-98.		0
1049	RNA sequence analysis of nasopharyngeal swabs from asymptomatic and mildly symptomatic patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 122, 449-460.	1.5	3
1050	Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	107
1051	Multifaceted Assessment of Wastewater-Based Epidemiology for SARS-CoV-2 in Selected Urban Communities in Davao City, Philippines: A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8789.	1.2	5
1053	A Comparison of Bioinformatics Pipelines for Enrichment Illumina Next Generation Sequencing Systems in Detecting SARS-CoV-2 Virus Strains. <i>Genes</i> , 2022, 13, 1330.	1.0	3
1054	Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	9
1055	Interferon resistance of emerging SARS-CoV-2 variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	63
1056	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. <i>Pathogens</i> , 2022, 11, 837.	1.2	0
1057	Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. <i>International Journal of Biological Sciences</i> , 2022, 18, 4642-4647.	2.6	4
1058	Possible intraindividual evolution of SARS-CoV-2 in nasopharyngeal and anal swab in an octogenarian: a case report. <i>Germes</i> , 2022, 12, 298-303.	0.5	0
1059	The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. <i>F1000Research</i> , 0, 11, 353.	0.8	0
1060	The Role of Lebanon in the COVID-19 Butterfly Effect: The B.1.398 Example. <i>Viruses</i> , 2022, 14, 1640.	1.5	3
1061	Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. <i>Nature Communications</i> , 2022, 13, .	5.8	28

#	ARTICLE	IF	CITATIONS
1062	Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.	1.5	27
1063	Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19. <i>Viruses</i> , 2022, 14, 1769.	1.5	1
1064	De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	9
1065	Structural Analysis of the Spike Protein of SARS-CoV-2 Variants and Other Betacoronaviruses Using Molecular Dynamics. <i>ChemPhysChem</i> , 0, , .	1.0	0
1066	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1067	Physical-Chemical Regulation of Membrane Receptors Dynamics in Viral Invasion and Immune Defense. <i>Journal of Molecular Biology</i> , 2023, 435, 167800.	2.0	2
1068	SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
1069	Flexible multiplex PCR to detect SARS-CoV-2, coronavirus OC43 and influenza A virus in nasopharyngeal swab samples. <i>Journal of Applied Microbiology</i> , 2022, 133, 3534-3545.	1.4	2
1070	STArS (STrain-Amplicon-Seq), a targeted Nanopore sequencing workflow for SARS-CoV-2 diagnostics and genotyping. <i>Biology Methods and Protocols</i> , 0, , .	1.0	0
1071	Molecular dynamic simulation suggests stronger interaction of Omicron-spike with ACE2 than wild but weaker than Delta SARS-CoV-2 can be blocked by engineered S1-RBD fraction. <i>Structural Chemistry</i> , 2022, 33, 1755-1769.	1.0	9
1072	Predicting Adhesive Free Energies of Polymer-Surface Interactions with Machine Learning. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 37161-37169.	4.0	13
1073	Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling. <i>Journal of Virology</i> , 2022, 96, .	1.5	7
1074	Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern. <i>Viruses</i> , 2022, 14, 1865.	1.5	1
1075	In Silico Evaluation of CRISPR-Based Assays for Effective Detection of SARS-CoV-2. <i>Pathogens</i> , 2022, 11, 968.	1.2	0
1076	Molecular Dynamics Analysis of Fast-Spreading Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Their Effects on the Interaction with Human Angiotensin-Converting Enzyme 2. <i>ACS Omega</i> , 2022, 7, 30700-30709.	1.6	6
1077	Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9659.	1.8	3
1078	SARS-CoV-2 genome variations and evolution patterns in Egypt: a multi-center study. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1081	Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. <i>Scientific Reports</i> , 2022, 12, .	1.6	26

#	ARTICLE	IF	CITATIONS
1082	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	1.8	47
1083	The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: A comparative analysis of the early and current strains. Journal of Medical Virology, 0, , .	2.5	1
1084	Contrasting Patterns in the Early Stage of SARS-CoV-2 Evolution between Humans and Minks. Molecular Biology and Evolution, 2022, 39, .	3.5	2
1086	Genomic surveillance of SARS-CoV-2 by sequencing the RBD region using Sanger sequencing from North Kerala. Frontiers in Public Health, 0, 10, .	1.3	2
1087	Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus. Microorganisms, 2022, 10, 1688.	1.6	2
1088	The New SARS-CoV-2 Variants and Their Epidemiological Impact in Mexico. MBio, 2022, 13, .	1.8	6
1089	Perspective Chapter: Tracking Trails of SARS CoV-2 - Variants to Therapy. Infectious Diseases, 0, , .	4.0	0
1090	Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019-2022. PLoS ONE, 2022, 17, e0271074.	1.1	14
1091	A study protocol to prepare an RBD protein for vaccine against COVID-19. F1000Research, 0, 10, 943.	0.8	0
1092	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. 3 Biotech, 2022, 12, .	1.1	4
1093	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. International Immunopharmacology, 2022, 111, 109128.	1.7	9
1094	Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. Virus Research, 2022, 319, 198882.	1.1	10
1095	A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nature Communications, 2022, 13, .	5.8	51
1096	Sustainable policy: Don't get infected and don't infect others. Journal of Hazardous Materials Advances, 2022, 8, 100165.	1.2	4
1097	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. Biomedical Engineering Advances, 2022, 4, 100054.	2.2	3
1098	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
1099	Genetics and Biological Characteristics of SARS-CoV-2. , 2022, , 49-66.		0
1100	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. International Journal of Biological Sciences, 2022, 18, 4781-4791.	2.6	5

#	ARTICLE	IF	CITATIONS
1101	Biophysical and structural characterizations of the effects of mutations on the structure-activity relationships of SARS-CoV-2 spike protein. <i>Methods in Enzymology</i> , 2022, , 299-321.	0.4	2
1104	SARS-CoV-2 does not infect pigs, but this has to be verified regularly. <i>Xenotransplantation</i> , 2022, 29, .	1.6	3
1105	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
1106	Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1107	The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness. <i>Scientific Reports</i> , 2022, 12, .	1.6	41
1108	RNA structure-altering mutations underlying positive selection on Spike protein reveal novel putative signatures to trace crossing host-species barriers in <i>Betacoronavirus</i> . <i>RNA Biology</i> , 2022, 19, 1019-1044.	1.5	2
1109	Comparison of Intracellular Transcriptional Response of NHBE Cells to Infection with SARS-CoV-2 Washington and New York Strains. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
1110	Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1112	The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	6
1113	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
1114	Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice. <i>European Journal of Immunology</i> , 2022, 52, 1768-1775.	1.6	8
1116	An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. <i>Science China Life Sciences</i> , 0, , .	2.3	2
1117	Quantifying Mutational Response to Track the Evolution of SARS-CoV-2 Spike Variants: Introducing a Statistical-Mechanics-Guided Machine Learning Method. <i>Journal of Physical Chemistry B</i> , 2022, 126, 7895-7905.	1.2	5
1118	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
1119	A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
1120	Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics. <i>Viruses</i> , 2022, 14, 2017.	1.5	3
1121	On the Origins of Omicron's Unique Spike Gene Insertion. <i>Vaccines</i> , 2022, 10, 1509.	2.1	10
1122	Intrahost SARS-CoV-2 k-mer Identification Method (iSKIM) for Rapid Detection of Mutations of Concern Reveals Emergence of Global Mutation Patterns. <i>Viruses</i> , 2022, 14, 2128.	1.5	0

#	ARTICLE	IF	CITATIONS
1124	Delta variant: Partially sensitive to vaccination, but still worth global attention. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 227-235.	1.0	2
1125	Virological, Epidemiological Features and Prevention of SARS-CoV-2 Omicron (B.1.1.529) Variant: A Review. <i>Kocaeli Üniversitesi Sağlık Bilimleri Dergisi</i> , 0, , 162-171.	0.3	0
1126	Molecular characterization of SARS-CoV-2 from the saliva of patients in the Republic of Korea in 2020. <i>Health Science Reports</i> , 2022, 5, .	0.6	2
1127	The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype. <i>Nature Communications</i> , 2022, 13, .	5.8	26
1130	<i>Ganoderma microsporum</i> immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113766.	2.5	6
1131	Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. <i>Computers in Biology and Medicine</i> , 2022, 150, 106129.	3.9	6
1133	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
1134	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
1135	SARS-CoV-2 down-regulates ACE2 through lysosomal degradation. <i>Molecular Biology of the Cell</i> , 2022, 33, .	0.9	19
1136	Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants. <i>Viruses</i> , 2022, 14, 2301.	1.5	6
1137	Systematic benchmarking of nanopore Q20+ kit in SARS-CoV-2 whole genome sequencing. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	11
1138	Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12516.	1.8	4
1139	Tracking contemporary microbial evolution in a changing ocean. <i>Trends in Microbiology</i> , 2023, 31, 336-345.	3.5	4
1140	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
1141	High-Throughput Assay for Identifying Diverse Antagonists of the Binding Interaction between the ACE2 Receptor and the Dynamic Spike Proteins of SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2022, 8, 2259-2270.	1.8	0
1143	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. <i>Nature Medicine</i> , 2023, 29, 247-257.	15.2	98
1144	Targeting an evolutionarily conserved E-L-E motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2. , 2022, 1, .		7
1145	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .	4.0	0

#	ARTICLE	IF	CITATIONS
1147	Computational analysis of interior mutations of SARS-CoV-2 Spike protein suggest a balance of protein stability and S2: S1 separation propensity. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 6078-6086.	1.9	0
1148	Comparison of Dose-Response Relationships for Two Isolates of SARS-CoV-2 in a Nonhuman Primate Model of Inhalational COVID-19. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2022, 35, 296-306.	0.7	3
1149	Photodynamic viral inactivation assisted by photosensitizers. <i>Materials Today Physics</i> , 2022, 28, 100882.	2.9	6
1150	Genomic evolution of SARS-CoV-2 in Reunion Island. <i>Infection, Genetics and Evolution</i> , 2022, 106, 105381.	1.0	1
1151	Astersaponin I from <i>Aster koraiensis</i> is a natural viral fusion blocker that inhibits the infection of SARS-CoV-2 variants and syncytium formation. <i>Antiviral Research</i> , 2022, 208, 105428.	1.9	4
1152	The Impact and Progression of the COVID-19 Pandemic in Bulgaria in Its First Two Years. <i>Vaccines</i> , 2022, 10, 1901.	2.1	5
1153	Model-informed COVID-19 exit strategy with projections of SARS-CoV-2 infections generated by variants in the Republic of Korea. <i>BMC Public Health</i> , 2022, 22, .	1.2	0
1154	A self-assembling split aptamer multiplex assay for SARS-COVID19 and miniaturization of a malachite green DNA-based aptamer. <i>Sensors and Actuators Reports</i> , 2022, 4, 100125.	2.3	2
1155	SARS-CoV-2 variants: Impact on biological and clinical outcome. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
1156	Combined effect of traditional Chinese herbal-based formulations Jing Si herbal tea and Jing Si nasal drop inhibits adhesion and transmission of SARS-CoV2 in diabetic SKH-1 mice. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1157	A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8
1160	Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection. <i>Medical Microbiology and Immunology</i> , 2023, 212, 25-34.	2.6	4
1161	Structural effects of spike protein D614G mutation in SARS-CoV-2. <i>Biophysical Journal</i> , 2023, 122, 2910-2920.	0.2	11
1162	Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1. <i>Viruses</i> , 2022, 14, 2475.	1.5	0
1163	ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner. <i>Communications Biology</i> , 2022, 5, .	2.0	13
1164	Conformational stability of SARS-CoV-2 glycoprotein spike variants. <i>IScience</i> , 2023, 26, 105696.	1.9	5
1165	Recent advances in regenerative biomaterials. <i>Regenerative Biomaterials</i> , 2022, 9, .	2.4	54
1166	Interference reduction isothermal nucleic acid amplification strategy for COVID-19 variant detection. <i>Sensors and Actuators B: Chemical</i> , 2023, 377, 133006.	4.0	2

#	ARTICLE	IF	CITATIONS
1167	Molecular Evolution of the Novel Coronavirus SARS-CoV-2. <i>Journal of Evolutionary Science</i> , 2020, 1, 53-64.	0.4	1
1169	Structural evolution of Delta lineage of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2023, 226, 1116-1140.	3.6	5
1170	An Overview of Repurposed Drugs for Potential COVID-19 Treatment. <i>Antibiotics</i> , 2022, 11, 1678.	1.5	3
1171	Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
1172	A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins. <i>Nature Chemical Biology</i> , 2023, 19, 284-291.	3.9	7
1173	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
1174	Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. <i>Cell Host and Microbe</i> , 2023, 31, 9-17.e3.	5.1	163
1175	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1176	Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity. <i>Biology</i> , 2022, 11, 1786.	1.3	4
1177	Tracing the First Days of the SARS-CoV-2 Pandemic in Greece and the Role of the First Imported Group of Travelers. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	0
1178	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
1179	Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawaiï€™i to facilitate public-health policies. <i>PLoS ONE</i> , 2022, 17, e0278287.	1.1	0
1180	The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant. <i>IScience</i> , 2022, 25, 105720.	1.9	27
1181	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. <i>Nature Medicine</i> , 2023, 29, 344-347.	15.2	249
1182	Single-virus tracking reveals variant SARS-CoV-2 spike proteins induce ACE2-independent membrane interactions. <i>Science Advances</i> , 2022, 8, .	4.7	9
1183	Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1010970.	2.1	13
1184	Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design. <i>IScience</i> , 2023, 26, 105855.	1.9	7
1186	Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. <i>Microorganisms</i> , 2023, 11, 30.	1.6	11

#	ARTICLE	IF	CITATIONS
1187	A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2. <i>3 Biotech</i> , 2023, 13, .	1.1	2
1188	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1189	Analysis of research hotspots in COVID-19 genomics based on citespace software: Bibliometric analysis. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	4
1190	Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. <i>Vaccines</i> , 2022, 10, 2111.	2.1	1
1191	Isolation and characterization of a SARS-CoV-2 variant with a Q677H mutation in the spike protein. <i>Archives of Virology</i> , 2023, 168, .	0.9	1
1192	Reverse genetic systems of SARS-CoV-2 for antiviral research. <i>Antiviral Research</i> , 2023, 210, 105486.	1.9	12
1193	Three on Three: Universal and High-Affinity Molecular Recognition of the Symmetric Homotrimeric Spike Protein of SARS-CoV-2 with a Symmetric Homotrimeric Aptamer. <i>Journal of the American Chemical Society</i> , 2022, 144, 23465-23473.	6.6	15
1194	Genomic landscape of alpha-variant of SARS-CoV-2 circulated in Pakistan. <i>PLoS ONE</i> , 2022, 17, e0276171.	1.1	5
1195	The establishment of COPD organoids to study host-pathogen interaction reveals enhanced viral fitness of SARS-CoV-2 in bronchi. <i>Nature Communications</i> , 2022, 13, .	5.8	10
1196	Mucociliary transport deficiency and disease progression in Syrian hamsters with SARS-CoV-2 infection. <i>JCI Insight</i> , 2023, 8, .	2.3	6
1198	Attenuation and Degeneration of SARS-CoV-2 Despite Adaptive Evolution. <i>Cureus</i> , 2023, , .	0.2	0
1199	Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
1200	Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020â€“2022. <i>Archives of Virology</i> , 2023, 168, .	0.9	18
1201	Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	11
1202	Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2023, 25, 2304-2319.	1.3	3
1203	In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations. <i>Bioengineering</i> , 2023, 10, 100.	1.6	10
1204	Vaccination with S _{pan}, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	14
1205	More or less deadly? A mathematical model that predicts SARS-CoV-2 evolutionary direction. <i>Computers in Biology and Medicine</i> , 2023, 153, 106510.	3.9	8

#	ARTICLE	IF	CITATIONS
1206	The race to understand immunopathology in COVID-19: Perspectives on the impact of quantitative approaches to understand within-host interactions. <i>ImmunInformatics</i> , 2023, 9, 100021.	1.2	1
1207	On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. <i>Viruses</i> , 2023, 15, 70.	1.5	2
1208	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. <i>Medical Microbiology and Immunology</i> , 2023, 212, 103-122.	2.6	18
1209	Use of the D614G Mutation of the SARS-CoV-2 Spike Protein as a Biophysical Model to Explain Coulomb's Law Function. <i>Creative Education</i> , 2023, 14, 103-110.	0.2	0
1211	Positive-strand RNA viruses—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1521, 46-66.	1.8	0
1212	SARS-CoV-2 evolution influences GBP and IFITM sensitivity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	12
1213	Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals. <i>ISME Journal</i> , 2023, 17, 549-560.	4.4	5
1214	Ancestral Lineage of SARS-CoV-2 Is More Stable in Human Biological Fluids than Alpha, Beta, and Omicron Variants of Concern. <i>Microbiology Spectrum</i> , 0, , .	1.2	2
1215	Unconventional secretion of unglycosylated ORF8 is critical for the cytokine storm during SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2023, 19, e1011128.	2.1	11
1218	Combining viral genomics and clinical data to assess risk factors for severe COVID-19 (mortality, ICU) Tj ETQq1 1 0.784314 rgBT /Overl 2023, 18, e0283447.	1.1	0
1219	Wastewater pandemic preparedness: Toward an end-to-end pathogen monitoring program. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	8
1220	Adaptive Evolution of the Spike Protein in Coronaviruses. <i>Molecular Biology and Evolution</i> , 2023, 40, .	3.5	6
1221	Infectivity of three Mayaro Virus geographic isolates in human cell lines. <i>Acta Tropica</i> , 2023, 242, 106894.	0.9	2
1223	Global SARS-CoV-2 genomic surveillance: What we have learned (so far). <i>Infection, Genetics and Evolution</i> , 2023, 108, 105405.	1.0	21
1224	Sequence analysis of SARS-CoV-2 Delta variant isolated from Makassar, South Sulawesi, Indonesia. <i>Heliyon</i> , 2023, 9, e13382.	1.4	3
1225	SARS-CoV-2 Spike Protein Post-Translational Modification Landscape and Its Impact on Protein Structure and Function via Computational Prediction. <i>Research</i> , 2023, 6, .	2.8	2
1226	Arrayed Imaging Reflectometry monitoring of anti-viral antibody production throughout vaccination and breakthrough Covid-19. <i>PLoS ONE</i> , 2023, 18, e0277846.	1.1	1
1227	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3255.	1.8	4

#	ARTICLE	IF	CITATIONS
1228	An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection. <i>Nature Materials</i> , 2023, 22, 903-912.	13.3	13
1231	A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. <i>Cell</i> , 2023, 186, 1263-1278.e20.	13.5	54
1232	SARSMutOnto: An Ontology for SARS-CoV-2 Lineages and Mutations. <i>Viruses</i> , 2023, 15, 505.	1.5	1
1233	Mathematical Modeling of SARS-CoV-2 Omicron Wave under Vaccination Effects. <i>Computation</i> , 2023, 11, 36.	1.0	9
1234	Origin and evolution of SARS-CoV-2. <i>European Physical Journal Plus</i> , 2023, 138, .	1.2	16
1235	Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida. <i>Viruses</i> , 2023, 15, 593.	1.5	2
1236	Global landscape of SARS-CoV-2 mutations and conserved regions. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	26
1237	SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. <i>Viruses</i> , 2023, 15, 639.	1.5	1
1239	Characteristics of Cardiac Abnormalities in Pediatric Patients With Acute COVID-19. <i>Cureus</i> , 2023, , .	0.2	1
1240	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. <i>Nature Communications</i> , 2023, 14, .	5.8	21
1241	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
1242	Potential socioeconomic approaches for commercialized antimicrobial applications. , 2023, , 365-401.		0
1243	Timeline of changes in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics. <i>ELife</i> , 0, 12, .	2.8	16
1246	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
1247	Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity. <i>Coronaviruses</i> , 2023, 4, .	0.2	1
1248	Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. <i>MBio</i> , 2023, 14, .	1.8	9
1249	The E2 glycoprotein holds key residues for Mayaro virus adaptation to the urban <i>Aedes aegypti</i> mosquito. <i>PLoS Pathogens</i> , 2023, 19, e1010491.	2.1	4
1250	Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2023, 16, .	0.9	2

#	ARTICLE	IF	CITATIONS
1251	Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease. Protein Expression and Purification, 2023, 207, 106267.	0.6	2
1252	Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection. Nature Communications, 2023, 14, .	5.8	1
1253	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
1254	Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. IScience, 2023, 26, 106634.	1.9	1
1256	Transfer Learning Facilitates the Prediction of Polymerâ€™Surface Adhesion Strength. Journal of Chemical Theory and Computation, 2023, 19, 4631-4640.	2.3	3
1257	Genomic surveillance of SARSâ€™CoVâ€™2 strains circulating in Iran during six waves of the pandemic. Influenza and Other Respiratory Viruses, 2023, 17, .	1.5	5
1258	Statistical analysis and data visualization of Indonesia and Malaysia SARS Cov-2 metadata. AIP Conference Proceedings, 2023, , .	0.3	0
1260	SARS-CoV-2 Variants by Whole-Genome Sequencing in a University Hospital in Bangkok: First to Third COVID-19 Waves. Pathogens, 2023, 12, 626.	1.2	0
1261	Multiplex Assays Enable Simultaneous Detection and Identification of SARS-CoV-2 Variants of Concern in Clinical and Wastewater Samples. ACS Measurement Science Au, 2023, 3, 258-268.	1.9	4
1262	Wastewater surveillance of SARS-CoV-2 genomic populations on a country-wide scale through targeted sequencing. PLoS ONE, 2023, 18, e0284483.	1.1	4
1273	The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern. Advances in Experimental Medicine and Biology, 2023, , 3-26.	0.8	0
1291	Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy. Current Microbiology, 2023, 80, .	1.0	1
1304	Chronicing the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Clinical and Experimental Medicine, 0, , .	1.9	0
1312	Antiviral Phytocompounds Against Animal-to-Human Transmittable SARS-CoV-2. , 2023, , 189-224.		0
1315	Semantic and Population Analysis of the Genetic Targets Related to COVID-19 and Its Association with Genes and Diseases. Advances in Experimental Medicine and Biology, 2023, , 59-78.	0.8	1
1358	Understanding Epidemic Multi-wave Patterns via Machine Learning Clustering and the Epidemic Renormalization Group. Fields Institute Communications, 2023, , 55-86.	0.6	0